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2INTRODUCTION
The latest human genome data reveals that the total number of genes for our species is
around 30,000, far fewer than previously predicted. The data confirm that humans of all
ethnic backgrounds share 99.99 percent of the same genetic code. Individual variations
comprise only 0.01 percent of the entire sequence, which includes 2.91 billion base
pairs.
So far it appears that genes tend to cluster along just a few of the chromosomes (e.g. 17,
19, 22) while others appear quite barren. Researchers have long been puzzled by that
fact that nearly one quarter of the human genome contains sequences that lack protein-
coding genes, so-called junk DNA.  About one-fourth of the genome could be
considered deserts, with lengthy gene-free segments. More than a third of the genome
(35.3 percent) contains repetitive sequences, suggesting that this so-called "junk DNA"
deserves further study. In addition to repeated segments, there is also renewed interest
in the 2.1 million scraps of DNA known as SNPs, or single nucleotide polymorphisms.
While the new data suggest most of these are harmless, some may underlie certain
disease processes.
The discovery that the human genome may only contain around 30,000 genes is one of
the most surprising findings of the world wide research effort. The good news is that
this may make it easier to identify the functions of the genes, any of which could be
promising targets for drug development. However researchers are already moving away
from the 'one gene- one protein' idea to the study of complex interactions between genes
that appear to have different functions in different contexts. Now that the basic structure
of the genome has been identified, it opens the way for an even more complex area of
study functional genomics, dedicated to finding out the function of single and multiple
interactive genes.
Genetic variation in the human genome
The completion of the initial draft of the human genome sequence (38) provided the
first in-depth description of the different components of the human genome (table1) and
considerable information about its gene content and gene positions. The genome
sequence has been used extensively as a starting point for many subsequent studies
3focusing on the function of genes or the functional elements of particular loci linked to
disease. Recently, human genetics shifted to large-scale studies of human genome
variation. The large-scale polymorphism data that are made available can now be used
to efficiently study genetic differences among humans.
The post-genomic research in human and population genetics is centred around the
study of the patterns of genetic variation across the genome and among populations with
the aim of understanding the origin of complex disease and the evolutionary history of
our species.
Variation in the human genome sequence plays a powerful but poorly understood role in
the etiology of common medical conditions. Because the vast majority of
heterozygosity in the human population is attributable to common variants and because
the evolutionary history of common human diseases (which determined the allele
spectrum for causal alleles) is not yet known, one promising approach is to
comprehensively test common genetic variation for association to medical conditions
(1–3). This approach is increasingly practical because 4 million (4, 5) of the estimated
10 million (6) common single nucleotide polymorphisms (SNPs) are already known.
Single nucleotide polymorphisms (SNPs) most often result from base substitutions
occurring through a nonrepaired error that occurs during DNA replication; other causes
of DNA polymorphisms include gene conversion and duplication.
The mutation rate at most positions of the human genome is relatively low (on the order
of 10_8 substitution per base pair per generation) compared with the most recent
common ancestor of any two individuals (on the order of 10,000 generations).
Therefore, the vast majority of allelic differences between individuals are inherited
rather than de novo mutations. Two individuals sharing the same allele at one position
are most likely identical by descent (for this specific portion of the DNA) rather than
through two independent mutations (i.e., homoplasy).
After a mutant allele is introduced in the gene pool, its fate is determined by the
interaction of two evolutionary forces: random genetic drift and natural selection. Drift
affects the distribution of a SNP in the population by random sampling of different
alleles at each generation (only a small fraction of all possible gametes are transmitted
to the next generation). If only drift acts on a particular region of the genome, a SNP
frequency varies randomly from generation to generation until one allele eventually
reaches fixation (either 100% or 0%), and the time before fixation occurs is mainly
determined by the population size. In other words, if only genetic drift acts,
4polymorphisms are only transient products of random fluctuations. However, natural
selection affects the probability that a particular variant is passed to the next generation.
It can either increase the probability and speed of fixation of an newly arisen allele if
the mutant allele confers a fitness advantage (i.e., selective sweep or positive selection),
remove new deleterious variants from the gene pool (i.e., negative selection), or
maintain several alleles in the gene pool over extended periods of time (i.e., balancing
selection).
da Feuk et al., 2006
Whereas mutations are generated essentially randomly in DNA molecules and random
genetic drift affects chromosomes as a whole, selection, in recombining genomes such
as humans, acts differently on distinct regions of the genome. Consequently, the level of
polymorphism varies greatly between different portions of the genome. For example,
regions of noncoding DNA (introns and intergenic regions) typically harbor a much
higher diversity than coding DNA (25), regulatory elements (such as promoters or
5splicing sites), or conserved nongenic elements (2, 17). Similarly, within exons,
synonymous and nonsynonymous positions differ in their diversity, as do, at a lower
scale, twofold from fourfold degenerated sites (i.e., nucleotides that can be changed
into, respectively, one or any other nucleotide and still code for the same amino acid)
(25). Diversity also varies along the genome over several Megabases, even after
correcting for gene or Guanine-Cytosine (GC) content (27). This large-scale variation
probably represents differences in recombination rates that affect the frequency of SNPs
(either directly through a putative mutagenic effect or indirectly via background
selection) (27). If one considers the distribution of genetic diversity, not across regions
of the genome, but across individuals, the frequencies of DNA polymorphisms also
differ greatly. For one locus this is often summarized by the frequency spectrum that
displays the frequency of all SNPs in a population. In a random mating population of
constant size and without selection acting at the locus considered, most SNPs are
expected to be present at low frequency and only found in one or few individuals,
whereas very few SNPs will be common (Figure 1).
Fig. 1
This figure shows the distribution of polymorphic sites according to their minor allele frequency (on the x
axis). The expected distribution under the standard neutral model (i.e., a pan-mictic population of
constant size in which genetic variation is not affected by natural selection) is displayed in gray. The
distributions of single nucleotide polymorphisms under a model of population growth and population
substructure are displayed respectively, in green and orange. The observed distributions in the HapMap
and ENCODE data set are shown in deep blue and light blue (for the individuals of European ancestry),
respectively.
6Deviations from this pattern may reflect violation of either the neutrality of the loci or
of the demographic assumptions. For example, population growth and positive selection
increase the proportion of rare alleles (i.e., alleles with low frequency), whereas
balancing selection and population substructure increase the proportion of intermediate
alleles (Figure 1). Analyzing the frequency spectrum is one of the most common tools
in population genetics, and many tests of neutrality rely on it directly or indirectly.
Most of the recent large-scale projects that generated genome-wide polymorphism data
used genotyping of selected SNPs (rather than more expensive and less high-throughput
resequencing), which introduces a skew in the frequency spectrum, especially if the
project focuses on intermediate frequency polymorphisms, as in the HapMap project
(Figure 1). Frequency spectra obtained from such data can be adjusted to take into
account the ascertainment bias (see, e.g., 49, 50), but a reliable reconstruction of the
evolutionary history of a particular locus currently still requires resequencing data that
produce unbiased diversity estimates and allow more rigorous testing of neutrality.
Recombination, Haplotypes and Haplotype Blocks
One of the most amazing developments in our understanding of the organization of
genetic diversity concerns the phenomenon of recombination and its consequences on
the allelic correlations between neighboring SNPs. Recombination refers to crossovers
and the exchange of chromatid fragments during meiosis.
In designing and interpreting association studies of genotype and phenotype, it is
necessary to understand the structure of haplotypes in the human genome. Haplotypes
are the particular combinations of alleles observed in a population. When a new
mutation arises, it does so on a specific chromosomal haplotype. The association
between each mutant allele and its ancestral haplotype is disrupted only by mutation and
recombination in subsequent generations.
Thus, it should be possible to track each variant allele in the population by identifying
(through the use of anonymous genetic markers) the particular ancestral segment on
which it arose.
7Fig. 2
Because each position can be hit only once by a mutation, one should end up with three
different possible combinations if no haplotype is lost by genetic drift or eliminated by
selection (Figure 2d ). This nonrandom association of alleles (on the figure the blue
allele is always associated with the red) is referred to as linkage disequilibrium (LD). If
a crossover occurs between the two polymorphic positions, it may generate a fourth
haplotype and break down LD between the two markers (Figure 2e). Interestingly,
recombination does not occur evenly but happens much more frequently in a small
fraction of the genome. These hot spots of recombination (typically 1–2 kb long) are
frequent across the genome (roughly 1 every 50 kb) and account for more than 80% of
8all recombination (15, 42, 46). Hot spots of recombination appear to be highly dynamic
and at least some of them differ in intensity and/or location between humans and
chimpanzees as well as possibly between human populations (15, 58, 59, 76). This may
influence the design of association studies and the choice of markers for studying a
given population, but because recombination rates seem conserved among human
populations over a larger scale (>1 Mb), variations in recombination pattern among
humans are unlikely to affect linkage studies (34, 64).
A popular and simple way to describe patterns of genetic diversity is to partition
chromosomes into “blocks” of SNPs in high LD with each other (23). This usually
allows summarizing polymorphism diversity into three to five common haplotypes that
account for most of the sample variability. However, one should keep in mind that the
definition and particularly the limits of these entities are highly arbitrary, as the
resulting block depend both on the SNP density and on the number of individuals
studied. These “blocks” should not be a priori considered as stretches of DNA sequence
where no recombination occurs, separated from each other by recombination hot spots
(even if this will be true in some instances). Note that the LD patterns observed in a
sample result both from recombination events and the population history of this sample
(56, 74, 75).
Haplotype blocks refer to sites of closely located SNPs which are inherited in blocks.
Regions corresponding to blocks have a few common haplotypes which account for a
large proportion of chromosomes. Identification of haplotype blocks is a way of
examining the extent of LD in the genome, which generally provides useful information
for the planning of association studies. The aim is to identify a minimal subset of SNPs
that can characterize the most common haplotypes. In each block, a small fraction of
single-nucleotide polymorphisms (SNPs), referred to as "tag SNPs," can be used to
distinguish a large fraction of the haplotypes. These tag SNPs can potentially be
extremely useful for association studies, in that it may not be necessary to genotype all
SNPs.
9The "Hap-Map" project (http://www.hapmap.org/index.html.en) describes haplotype
blocks in the human genome.
The rationale of such major enterprise is that this information will make it possible to
conduct disease gene association studies more quickly and efficiently than ever before,
resulting in the more rapid elucidation of the variants that predispose to disease and
influence drug response. Recent surveys of haplotype diversity in a number of genomic
segments, and up to a chromosome, support the notion of haplotype "blocks" of limited
diversity. While it is not clear how these finding will translate to other regions or
populations, it seems imminent that large studies to elucidate the patterns of genomic
variation will be carried out.
With the imminent flood of data from the Haplotype Map project, there is an urgent
need to extend haplotype-related computational methods to the whole-genome scale.
There are many fundamental computational and statistical problems to solve: how to
calculate genome-wide haplotypes and determine haplotype block boundaries on
sequence, how to find the optimal number of SNPs per haplotype block, how to account
for the variation in LD across different populations, how to find the most informative
SNPs for each haplotype block, how to deal with uncertainty in annotations and map
locations, development of controls for spurious statistical association, the effects of
population substructure, estimation of statistical significance, effects of genotyping
error, how to manage and represent the large amount of data, methods for modeling the
genotyping process in silico to avoid artifacts and failures in the massive genotyping
projects, etc. Finally, methodologies to use the haplotype information for more efficient
design and analysis of whole-genome association studies are in their infancy and
deserve attention.
Gabriel et al. (2002) examines whether there is similar haplotype block-structure
between and within populations (Nigeria/Yoruba, Asia, African Americans, Europeans),
Fig.3.
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         Fig. 3-  Distribution of haplotypes across populations (Gabriel et al., 2002)
Haplotype methods have contributed to the identification of genes for Mendelian
diseases   (7–9) and, recently, disorders that are both common and complex in
inheritance (10– 12).
Many studies have examined allelic associations [also termed “linkage disequilibrium”
(LD)] across one or a few gene regions. These studies have generally concluded that
linkage disequilibrium is extremely variable within and among loci and populations
[reviewed in (13– 15)]. Recently, examination of a higher density of markers over
contiguous regions (16–18) suggested a surprisingly simple pattern: blocks of variable
length over which only a few common haplotypes are observed punctuated by sites at
which recombination could be inferred in the history of the sample.
The major attraction of haplotype methods is the idea that common haplotypes capture
most of the genetic variation across sizable regions and that these haplotypes (and the
undiscovered variants they contain) can be tested with the use of a small number of
haplotype tag SNPs (“htSNPs”) (16, 18, 19, 39). A number of reports (39–41), however,
have suggested that many SNPs fail to conform to the underlying haplotype structure
and would be missed by haplotype-based approaches.
Recent genomic surveys have produced high-resolution haplotype information, but only
in a small number of human populations.
Conrad et al., (2006) report haplotype structure across 12 Mb of DNA sequence in 927
individuals representing 52 populations. The geographic distribution of haplotypes
reflects human history, with a loss of haplotype diversity as distance increases from
Africa. Although the extent of linkage disequilibrium (LD) varies markedly across
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populations, considerable sharing of haplotype structure exists, and inferred
recombination hotspot locations generally match across groups. The study provides the
first data on global haplotype variation across multiple megabases of sequence in
multiple genomic regions. Global patterns of haplotype variation accord well with a
population model in which genetic variation passed through a serial dilution process as
humans spread progressively further from our African source (fig 4).
In the future, autosomal haplotype data will surely provide an important tool for
unravelling the history of human migrations.
A related application of haplotype data is identifying genomic regions that have been
targets of natural selection2,6,7. Such tests, which attempt to identify unusually long
common haplotypes likely to have reached high frequencies as a result of recent natural
selection, have reduced power in populations that are strongly bottlenecked owing to the
property that common haplotypes are often extremely long even in neutral regions.
Fig 4
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Available resources for studying human genetic diversity
The SNP Database
The single nucleotide polymorphism database (dbSNP) serves as a central depository of
SNPs in the public domain. It provides a description of the SNP and its flanking regions
and links to multiple National Center for Biotechnology Information (NCBI) Internet
pages. The latest release (Build 125) contains more than 27 million SNPs, more than 4
million of which lie within genes. More than 6 million SNPs have been validated and
are likely relatively common in the population. Frequency descriptions are available for
about 600,000 SNPs, but this figure will dramatically increase with the incorporation of
the HapMap phase II data in dbSNP.
The HapMap and Perlegen Projects
Both the International HapMap Consortium (2) and Perlegen Sciences (29) recently
produced and released genome-wide genotyping data in samples from several human
populations. In both cases, the goal was to cover the entire genome with common DNA
polymorphisms that are evenly spaced. The density obtained is of roughly 1 SNP every
2 kb for the Perlegen data set and of 1 every 3 kb for the first phase of the HapMap
project (and the latter density will increase rapidly up to 1 SNP every kilobase when
phase II is completed). Both data sets are freely available on the Internet. The
International HapMap Consortium (2) genotyped individuals from four populations:
Centre d’Etude du Polymorphisme Humain (CEPH) (Utah residents with Northern or
Western European ancestry), Yoruba from Ibadan (Nigeria), Han Chinese from Beijing
(China), and Japanese from Tokyo (Japan). The sampling scheme varies for different
populations: The Yoruba and CEPH individuals consist of 30 unrelated trios while the
Han Chinese and Japanese are represented by 45 and 44 unrelated individuals,
respectively.
The SNPs were chosen in order to obtain a high proportion of intermediate frequency
polymorphisms (i.e., with a minor allele frequency higher than 5%). This makes this
data set especially valuable for choosing markers for medical studies as they will likely
maximize the information for each individual, but it complicates their use in population
genetic analyses because the allele frequency spectra are biased (see above). Perlegen
Sciences analyzed three populations (CEPH, African Americans, and Han Chinese from
the Los Angeles area) represented by 23 or 24 individuals each.
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From natural variation to phenotypic differences
Our knowledge of “natural” genetic diversity in humans and its organization has greatly
progressed, notably with the results of genome-wide projects. The next step for human
geneticists will be to use this tremendous amount of information on natural variation to
unravel the still mostly mysterious connections between DNA and phenotypic
differences. Using the HapMap and Perlegen data sets, several groups have identified
regions with high levels of population differentiation, low levels of diversity, or
unusually long stretches of DNA sequence in high or complete LD (2, 8, 50, 72). All
these loci are promising candidates to further study the influence of natural selection on
the human genome.
Validating these regions, as well as integrating information from other species [such as
the chimpanzee genome sequence that was recently released (43)], will shed light on
where and how natural selection acted during human evolution to shape current human
genome diversity.
Additional studies are necessary to validate these potentially interesting loci as it is still
unclear whether these observations are actual genomic differences or artifacts of the
ascertainment in the choice of the SNPs.
One cannot reject the possibility that some of these loci may be chance events, given the
large amount of data analyzed. Resequencing the regions of interest in a large
worldwide sample (e.g., using the CEPH-HGDP panel) would help solve some of these
uncertainties and could contribute to the understanding of what makes or made humans
human. These results can also have important medical implications by identifying
alleles involved in common diseases. Under the assumption that at least some common
diseases are due to common variants, one would expect that the disease alleles may, in
particular environmental circumstances, confer a benefit to the carrier that would
balance the deleterious effect of the disease. Such loci would evolve under balancing
selection and thus could be identified by searching the entire genome for loci with a
local excess of diversity and highly differentiated haplotypes (70). Alternatively, some
common diseases may result from a change in environment during the last phases of
human evolution such that the derived protective alleles (formerly deleterious) have not
yet reached fixation in humans (16). These alleles should harbor the footprints of a
recent (in fact, ongoing) selective sweep [i.e., low diversity, excess of rare alleles,
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extended regions of high LD (48)] and could also be identified by a genome-wide
search for selected loci performed in healthy individuals.
Medical Genetics: Toward Genome-Wide Studies
The most important contribution from these large resources of human genetic diversity
will likely concern the medical field, with, hopefully, the identification of genes (and
their variants) involved in genetic disorders and a better understanding of the molecular
mechanisms leading to disease. Both Perlegen and the International HapMap data sets
can now be used to identify risk or protective alleles involving a particular disease. The
HapMap project favored this application by preferentially selecting intermediate allele
frequency polymorphisms that are more informative for linkage or association studies
(compared to rare alleles). Additionally, these data lead to a very precise description of
the LD patterns in the human genome.
Using a set of markers evenly distributed on the physical map (e.g., one marker every
ten kb) may be inefficient in testing a significant fraction of the genome with high
recombination rates, given that markers in these regions are poorly correlated and thus
may have not been “tagged” by the markers used.
Incorporating information about the recombination patterns while choosing the markers
allows one to use the LD information to aptly select SNPs [tag-SNPs (tSNPs)] for
efficient coverage of the genome. This will lead to a higher marker density in regions of
high recombination rate and fewer markers (and less redundancy) in regions of low
recombination rates. Thus, one can anticipate that these data will be successful to both
narrow down previously identified candidate regions using a denser map of markers
(37, 44) and to identify new candidate loci through whole genome association scans
(36).
The information and resources resulting from the recent completion of genome-wide
diversity projects will surely catalyze the discovery  of common genetic variants
affecting disease risk, and increase our understanding of gene expression regulation.
This is particularly promising for medical genetics, given the availability of numerous
genetic markers and adequate technologies to analyze thousands of individuals.
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CHAPTER 1
MOLECULAR VARIABILITY IN HAMP GENE PROMOTER AND CODING
REGION IN A COHORT OF HEMOCHROMATOSIS PATIENT
INTRODUCTION
Iron is ubiquitous in nature. During evolution, virtually all forms of life developed
various methods and means to keep iron at adequate levels and prevent deficiency. Iron
is essential for many intracellular functions by virtue of its ability to accept or donate
electrons. This same characteristic, however, allows free iron in solution to form highly
reactive free radicals that can lead to cell damage. The harmful effects are related to
increased oxidative stress and production of reactive oxygen species causing oxidative
damage to lipids, proteins, and nucleic acids. The appropriate regulation of systemic
iron homeostasis, therefore, is crucial for the survival and wellbeing of all complex
organisms, including humans. The average male human contains approximately 4 grams
of iron (Brittenham 1994). Under normal conditions approximately 1–2 mg of iron per
day enters the body via the enterocytes of the proximal small intestine. This newly
absorbed dietary iron is released into the circulation and binds to the serum protein
transferrin. Approximately 3 mg of iron circulates bound to transferrin and, although
this represents only a small proportion of total body iron, evidence is accumulating that
this iron compartment is vital for the maintenance of body iron homeostasis. Transferrin
bound iron is taken up by cells by transferrin receptor 1 (TfR1)-mediated endocytosis
(Huebers and Finch 1987). Most of the transferrin bound iron in the circulation is
destined for the developing erythrocytes of the bone marrow, where it is taken up at a
rate of approximately 22 mg of iron per day (Brittenham 1994), and used in the
production of haemoglobin. About 65–70% of body iron exists in this form in
circulating red blood cells. Old or damaged red blood cells are removed from the
circulation by the macrophages of the reticuloendothelial (RE) system, where iron is
released from haemoglobin and either stored in the intracellular iron storage protein
ferritin, or released back into the circulation as transferrin-bound iron. The cells of the
RE system release about 22 mg of iron per day, thus replacing the amount taken up by
the bone marrow. Other body cells also take up iron from the circulation via TfR1-
mediated endocytosis although in far lower
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amounts. This iron can be used to synthesize a wide range of iron containing
intracellular proteins, such as the haem containing cytochromes, and proteins containing
iron-sulfur clusters. Approximately 10–15% of body iron is present in such proteins,
with up to 80% of this found in muscle cell myoglobin. The remaining 20% of body
iron is present as storage iron, predominantly located in the macrophages of the RE
system and the hepatocytes of the liver. The movement of iron between these
compartments is a tightly regulated process that can be modulated according to the
body’s iron requirements. Individual cells maintain appropriate intracellular iron levels
by altering the expression of TfR1 on the cell surface (Huebers and Finch 1987). The
more iron each cell requires, the higher the expression of TfR1. While the uptake of iron
by cells is predominantly controlled locally by intracellular iron levels, iron release,
particularly from the cells of the RE system, liver and proximal small intestine, appears
to be regulated by systemic signals. Evidence now suggests that the control of cellular
iron efflux is the major regulatory point for the maintenance of systemic iron
homoestasis (Frazer and Anderson 2003). For example, the stimulation of
erythropoiesis following blood loss increases the iron requirements of the bone marrow.
To cope with this demand, the body increases cellular iron release, making available
iron stored in the macrophages of the RE system and hepatocytes of the liver. At the
same time, the increase in iron release by intestinal enterocytes allows iron taken up
from the diet to enter the circulation and replenish the body’s iron stores. Once
erythropoiesis and the demand for iron have reduced to normal levels, cellular iron
release also decreases to maintain iron homeostasis. The importance of tightly regulated
cellular iron release is evident from a number of pathological conditions in humans.
Patients with the genetic disorder HFE-associated haemochromatosis may develop
severe iron loading that can often result in tissue damage and possibly organ failure
(Fleming et al. 2005). This appears to be caused by inappropriately high iron release by
enterocytes and macrophages. As a result, iron normally stored in the RE system or lost
from the alimentary canal is released into the circulation, overwhelming the iron
binding capacity of transferrin, and allowing the formation non-transferrin bound iron
(Batey et al. 1980). This form of iron is very rapidly taken up by cells, particularly
hepatocytes, leading to iron overload (Brissot et al. 1985). Another pathological
condition involving altered iron release from cells is the anaemia of inflammation.
During an inflammatory response, iron release from cells decreases, lowering the level
of transferrin-bound iron in the circulation (Weiss and Goodnough 2005). This response
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probably evolved to assist the immune system to overcome infection by withholding
iron (a well recognized virulence factor for microorganisms) from invading pathogens.
However, in chronic inflammatory conditions, such as rheumatoid arthritis, the
transferrin saturation is reduced for long enough to compromise iron delivery to the
developing erythrocytes in the bone marrow, resulting in anaemia (Weiss and
Goodnough 2005). In both of the above pathological states, cellular iron release does
not reflect the body’s iron requirements. Due to its physiological importance, the
mechanism by which the body regulates iron release is the focus of intense scrutiny.
Fig.1 scheme of daily iron movement in the different body compartment
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HEREDITARY HEMOCHROMATOSIS
This term was introduced to define the association of widespread tissue injury with
massive tissue iron deposition1 and likely referred to a clinical entity named ‘‘bronze
diabetes’’2 and ‘‘cirrhose pigmentaire’’3 first reported in France in the second half of
the 19th century. After only one century the term was associated with an hereditary
disease4 and linked to the major histocompatibility class I complex A3, on the short arm
of chromosome 6.5 6 In 1996, the most prevalent HC gene, HFE, was cloned.7
However, once the HFE gene was identified, it appeared immediately clear that HFE
mutations accounted for most but not all cases of HC.8. Since then, unprecedented
progress in the field of iron genetics has led to the identification of new genes involved
in iron metabolism whose mutations are responsible for cases of hereditary iron storage
disorders. The term haemochromatosis (HC) (synonymous for hereditary or idiopathic
or primary haemochromatosis) defines an autosomal recessive disorder of iron
metabolism characterized by tissue iron overload potentially leading to multiorgan
disease, such as liver cirrhosis, endocrinopathy, and cardiomyopathy. The syndrome is
the result of a genetically determined failure to stop iron from entering the circulatory
pool when it is not needed. It is associated with pathogenic mutations of at least four
HC genes (that is, HFE, TfR2, HJV, and HAMP) and it is likely due to a regulatory
defect in iron homeostasis in the liver.9 Four basic features define HC and are
characteristic of the classic disorder related to HFE C282Y homozygosity (the prototype
for this subset and by far the most common form) and the rare disorders more recently
attributed to loss of TfR2, HAMP, or HJV . These features include: hereditary, usually
autosomal recessive, trait; iron overload initially involving the plasma compartment
(reflected in increasing serum transferrin saturation); iron overload subsequently
involving parenchymal cells (reflected in increasing serum ferritin) with the potential
for organ damage and disease; unimpaired erythropoiesis and optimal response to
phlebotomy.9 Established concepts regarding primary cause and molecular
pathogenesis of HC have been more or less all challenged by recent new discoveries,
particularly those pertaining to the genetic field. Based on this new information and on
circumstantial evidence provided by recent human and animal studies, a unifying
pathogenic model for HC is presented in this article.
HFE
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HFE is a major histocompatibility class I-like protein whose ancestral peptide binding
groove is too narrow to allow classic antigen presentation10 while a possible non-
classic immunological activity has been recently proposed.11 It is incapable of binding
iron.12 Interaction between HFE and the transferrin receptor, TfR1, which mediates
transferrin bound iron uptake by most cells,12 13 has been fully documented although
its biological effects are still uncertain. However, it is unclear whether the interaction of
HFE with TfR1 is key for the pathogenesis of HC.14–16 The C282Y mutation
(substitution of tyrosine for cysteine at position 282 due to a single base,
845G-.A), the most common pathogenic mutation of HFE, is associated with disruption
of a disulfide bond in HFE that is critical for its binding to b2 microglobulin.17 The
latter interaction is necessary for the stabilization (intracytoplasmic), transport, and
expression of HFE on the cell surface and endosomal membranes where HFE interacts
with TfR1. The H63D mutation, a common HFE mutation whose pathogenic
significance is still uncertain, does not impair HFE-TfR1 interaction. While the
biological function of HFE is still unknown, circumstantial evidence indicate that it
might be required for the synthesis of hepcidin, the iron hormone secreted by
hepatocytes.
TRANSFERRIN RECEPTOR 2 (TFR2)
In 1999, the gene for a second human transferrin receptor (TfR2) was cloned.18 Unlike
TfR1, the new receptor was found to be highly expressed in the liver and it was not
regulated by intracellular iron status.19 TfR2 mediates the uptake of transferrin bound
iron by hepatocytes,18 possibly through the mechanism of receptor mediated
endocytosis similar to that described for TfR1, but its in vitro affinity for transferring is
25–30-fold lower than that of TfR1.20 Yet, TfR2 mediated transferrin iron uptake may
be of importance in hepatocytes, which express a low number of TfR1. The biological
role and function of TFR2 remain unknown, but recent studies
suggests a role for TfR2 in hepcidin synthesis in the liver (see below). In fact, its
putative role in hepatocyte uptake of iron18 is difficult to reconcile with the HC
phenotype observed in humans with pathogenic TfR2 mutations21 and in TfR2
knockout mice.22 TfR2 does not seem to interact with HFE,20 but its persistent hepatic
expression during iron overload might conceivably reflect a contribution to the
modulation of hepcidin synthesis in this setting.
29
HEMOJUVELIN (HJV)
Hemojuvelin (also called HFE2, or repulsive guidance molecule C (RgmC)) is
transcribed from a gene of 4265 bp into a full length transcript with five spliced
isoforms.23 Analyses of hemojuvelin in human tissues detect substantial expression in
adult and fetal liver, heart, and skeletal muscle.23 The putative full length protein is 426
amino acids with a large RGM motif, homologous to repulsive guidance molecules
involved in neuronal cells migration; it contains a C terminal putative transmembrane
domain characteristic of a glycosylphosphatidylinositol linked membrane anchor (GPI
anchor). Removal of the GPI anchor or proteolysis would be expected to generate a
soluble form of hemojuvelin, suggesting that it can be present in either a soluble or a
cell associated form. The function of hemojuvelin is presently unknown. However,
hepcidin levels are depressed in individuals with HJV mutations,23 and in HJV
knockout mice,24 and a recent study in vitro indicated that HJV is a transcriptional
regulator of hepcidin25 (see below). In this study, cellular hemojuvelin positively
regulated hepcidin mRNA expression, and recombinant soluble hemojuvelin suppressed
hepcidin mRNA expression in primary human hepatocytes in a log linear dose
dependent manner, suggesting binding competition between soluble and cell associated
hemojuvelin.
HEPCIDIN (HAMP)
Hepcidin, the long awaited iron hormone, is an antimicrobial peptide produced by
hepatocytes in response to inflammatory stimuli and iron.26–28 It is the product of the
HAMP gene, consisting of three exons and two introns located on chromosomes 7 and
19 in mouse and humans, respectively. Humans and rats have a single HAMP gene 28,
whereas two functional genes, Hamp 1 and 2 are present in the mouse genome.29
Hepcidin mRNA is nearly confined to the liver. The transcript encodes a precursor
protein of 84 amino acids, including a putative 24 amino acid leader peptide, while the
circulating forms consist of only the C terminal portion (20 and 25 amino acid
peptides).
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In solution, the small cysteinerich hepcidin peptides form a distorted beta sheet with an
unusual vicinal disulphide bridge found at the turn of the hairpin, which is probably of
functional significance.30 Due to significant antibacterial and antifungal activities of the
C terminal peptide, hepcidin has been classified as a member of the cysteine-rich,
cationic, antimicrobial peptides, including the thionins and defensins. Evidence from
transgenic mouse models indicates that hepcidin is the principal downregulator of the
transport of iron across the small intestine and the placenta, and its release from
macrophages. In vivo injection of hepcidin into mice significantly reduced mucosal iron
uptake and transfer to the carcass, independently of iron status or presence of HFE,31 or
induces hypoferraemia in humans.32 The present view is that hepcidin downregulates
iron efflux from the intestine and macrophages by interacting with the main iron export
protein in mammals, ferroportin (FPN). In fact, it has been recently shown that hepcidin
binds to FPN in cultured cells stably expressing FPN and, following complex
internalisation, leads to FPN degradation.33
A UNIFYING PATHOGENIC MODEL FOR HAEMOCHROMATOSIS
The first biochemical manifestation of HC is an increase in transferrin saturation which
reflects an uncontrolled influx of iron into the bloodstream from enterocytes and
macrophages. Duodenal transfer of iron to plasma is inappropriately high for body iron
stores,49 suggesting downregulation failure in HC. Phlebotomy normally triggers sharp
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transient increases in absorption (from 1–2 mg/day to 5 mg/day), mainly to ensure bone
marrow supplies, but in HC this response is exaggerated (8–10 mg/day) and the rate
remains high for years.50 The end result is intestinal absorption of iron that generally
exceeds loss by approximately 3 mg/day in HC.51 While the only way that total body
iron can be increased is through increased intestinal iron absorption, macrophages
(normally a much more important source of plasma iron than either enterocytes or
hepatocytes)52 are also important in the pathogenesis of HC. They are invariably iron
poor in HC and seem to release more iron or to retain less transferrin bound iron than
their normal counterparts.9 Historically, the intestine has been seen as the primary site
of the defect in HC and studies showing that HFE is normally expressed in intestinal
crypts reinforced this idea leading to the development of a specific pathogenic model.9
This model attributed the relative iron deficiency of mature absorptive HC enterocytes
and increased intestinal iron absorption to an abnormal interaction between TfR1 and
mutant HFE in intestinal crypt cells. The presence in this model of C282Y mutant HFE
which is unable to interact with TfR1, leads to iron deficient crypt cells, which give rise
to iron deficient daughter cells. These cells are ‘‘programmed’’ to react to iron
starvation by hyperactively and persistently absorbing iron from the intestinal lumen
and transferring virtually all of it
into the bloodstream, regardless of actual erythropoietic needs. More recently, however,
this model has been challenged with the discovery of hepcidin and its central
involvement in iron homeostasis. Consequently, attention has moved to the liver as the
primary site of the defect in HC. The progressive expansion of the plasma iron pool in
HC, which occurs at a much faster rate in ‘‘juvenile’’ forms of the disorder (HJV and
HAMP related HC) compared with late onset forms (HFE and TfR2-related HC), is
likely the result of increased transfer of iron to the blood compartment from enterocytes
(that is, increased intestinal absorption) and from reticuloendothelial macrophages.9 As
mentioned above, the main regulator of iron efflux from enterocytes and macrophages
in humans is hepcidin. In HFE, TfR2, and HJV related HC, hepatic expression or
serum/urine levels of this peptide are inappropriately low.42 43 53 54 Its expression in
the liver is also significantly impaired in HFE, TfR2, and HJV knockout mice24 55–57
and hepatic deposition of iron in HFEKO animals can be prevented by hepcidin
overexpression.58 These findings suggests a unifying pathogenic model for all forms of
HC in which HFE, TfR2, and HJV are all independent but complimentary regulators of
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hepcidin synthesis in the liver (fig 1). Hypothetically, these three proteins may be
important for
sensing circulatory iron and turning on hepcidin gene transcription, albeit with different
mechanisms and functional impact: HFE might have a role in endosomes and/or plasma
membranes iron traffic even independently of TfR1; TfR2, highly expressed in
hepatocytes even during iron overload, might signal transferrin bound or unbound iron;
soluble and cell associated hemojuvelin might reciprocally regulate hepcidin expression
in response to changes in extracellular iron concentration: soluble HJV might even
signal the iron status of peripheral tissues, such as skeletal muscles where HJV also
seems to be expressed. When all three proteins function correctly (and the HAMP gene
that encodes hepcidin is normal), the amount of iron transferred
into the blood will be appropriate to body needs, and excessive iron deposition in tissues
will be avoided (fig 1A). The relative contributions of the three genes to this modulatory
process may be different, with a more substantial role assigned to HJV based on the
more severe iron overload phenotype associated with HJV mutations. Loss of one of the
minor regulatory proteins (HFE or TfR2 related HC) will result in an appreciable
increase in iron influx into the bloodstream but residual hepcidin activity will be
sustained by the second minor regulator and the major regulator, HJV
gene (fig 1B, C). The result is a mild ‘‘adult’’ HC phenotype, with gradual plasma iron
loading and gradual accumulation of iron in tissues. Loss of the ‘‘major’’ hepcidin
regulator, HJV, will produce a more dramatic effect on iron into the bloodstream and
result in a more severe, ‘‘juvenile’’, HC. Combined loss of HFE and TfR2 (HFE+TfR2
related HC) would theoretically result in much more rapid and substantial increases in
plasma iron and, consequently, greater iron overload in tissues: in short, a more severe
juvenile phenotype, not unlike that produced by loss of HJV. In fact, a recent study has
described patients with severe juvenile HC phenotype associated with combined
mutations of HFE and TfR2.59 Finally, complete loss of hepcidin (HAMP related HH),
in spite of normal HFE, TfR2, and HJV, will inevitably lead to massive uncontrolled
release of iron into the circulation and severe HC phenotype.
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HAMP GENE
HAMP gene is located in chromosome 19 q13.12. In Vega database
(http://vega.sanger.ac.uk/Homo_sapiens/) two different transcripts are reported, one
longer with an additional intron and an additional 5’ UTR that spans in a region of 4,43
Kb and one shorter characterized by only two introns that spans in a region of 2.64 Kb.
Considering the central role of this small peptide and the different stimuli to which it
has to respond the hypothesis that the gene has two promoters in order to get different
pathway of activation seems quite logical. Although logical the longer form of the gene
is actually observed in only one reports and in any other databases the protein is
reported only in the shorter version, thus in our study we considered the shortest one.
From deep researches in different databases merged that in the coding region of the
HAMP gene no polymorphic variants are reported.
THE STUDY
This data is consistent with the reported central role of the protein. Aim of our study is
to screen for new mutation the coding regions and the promoter of HAMP gene in 83
unrelated subjects characterized by high levels of iron in blood. As previously reported
HAMP gene plays a pivotal role in iron homeostasis, so we selected subjects that
presents physiological picture that can be related to juvenile hereditary
hemochromatosis. All the subjects participating the study where previously typed for
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the three major HFE mutations C282Y, H63D, S65C in order to exclude for the high
iron serum level an involvement of those variants.
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MATERIAL AND METHODS
Subjects: A total of 84 unrelated probands between 7 and 47 years of age with serum
transferrin saturation values between 40% to 99% were selected. The probands were
previously typed for the three most prevalent mutations related to hereditary
hemochromatosis: C282Y, H63D, S65C in the Hfe gene, and resulted negative. The
patients were referred from Clinical Hematologic, Interne Medicine from S. Orsola-
Malpighi hospital of Bologna.
Genetic analysis: All patients underwent mutation’s analysis in the HAMP gene.
DNA was isolated from peripheral blood lymphocytes using QI Amp DNA Blood Kit
(Quiagen Inc. Valencia, CA). All 3 exons flanking intronic sequences and the promoter
of the HAMP gene (Gene Bank AF041021), were amplified in 50 ?l standard PCR
containing 50 ng DNA using Ampli-Taq Gold and Gene-Amp PCR system 9700
thermocycler (Applied Biosystems).
Following verification of product size by agarose gel electrophoresis, amplicons were
denaturated at 95°C for 10 minutes and allowed to renature over 10 minutes to create
heteroduplices. Each fragment was run on an automated WAVE dHPLC (denaturated
High Performance Liquid Chromatography) instrument equipped with a DNA Sep®
column (transgenomic, San Jose, CA).
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All variant identified by the denaturing HPLC scanning were examined by direct
sequencing of both strands using the CEQ 8000 protocol for Taq-dye terminator cycle
sequencing on an automated CEQ 8000 DNA Sequencer ( Beckman Coulter Inc.,
Fullerton, CA) after a purification with Seq-Prep Kit (Gene Dia, Lammari, LU, Italy).
Results were analyzed with Sequencer software (Gene Codes Corp., Ann Arbor, MI).
Wherever possible the novel mutations detected were confirmed by specific restriction
analysis using commercial enzymes and digestion conditions suggested by the producer
(New England BioLabs Inc., Beverly, MA).
Nomenclature for the description of human sequence variations was referred to J.T. dan
Dunnan and Antonorakis.
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RESULTS
A total of 84 unrelated probands between 7 and 47 years of age with serum transferrin
saturation values between 40% to 99% were included in the study. The probands
resulted negative for the three most prevalent mutations related to hereditary
hemochromatosis in the HFE gene. All the 84 subject were screened for new mutations
in the coding region and the promoter of HAMP gene. The screening was assessed by
the use of DHPLC  technology. The three exons and the promoter were subdivided in 5
five amplicons, with a final score of 420 amplicons tested in the study. From the
analysis of amplicons only five variants were discovered.
DNA  4675 8514 8573 10802
HEP 2
E2F+E2R
DHPLC
WT WT ET ET
PROMOTORE
HEP 2
E2F+E2R
SEQ
\ \ IVS1-69 C-T 2392 C-G
E3F+ E3R
NEW DHPLC
WT WT ET ET
ESONE 1
E3F+ E3R
NEW  SEQ
\ \ IVS1-69 C-T 2392 C-G
HEP 4 (ex3-
4)
E4Fbis+E4R
DHPLC
WT ET ET ET
ESONE 2
HEP 4(ex3)
E4Fbis+E4R
SEQ
\ 4634 G-A 4502 C-T 4634 G-A
HEP 5(ex3-4)
E5F+E5R
DHPLC
ET ET WT ET
ESONE 3
HEP 5(ex3-4)
E5F+E5R
SEQ
4818 G-A 4634 G-A WT 4634 G-A
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One variant is in position 4502, is a transition C to T, this variant is reported in dbSNP
database, rs2293689, and is one of the SNPs typed in the HAPMAP project and in AFD.
Both on AFD and in HapMap project database the T allele is not reported in European
panel, therefore is the first time that this variant appear in European population.
The other three variants are reported for the first time and probably are to be considered
private. One variant is in the promoter region, in position –69, it is a transition C to T .
The position –69 is in the overlapping region of amplicon 1 and 2 so both in DHPLC
and sequence the signal of the transition was detected in the two different PCR
products.
In position 2392 we found a transversion C to G, it is in the coding region, but is
synonymous mutation, lysine to lysine. The position 2392 is in the overlapping region
of the amplicons 2 and 3, so it was confirmed both in DHPLC and sequence in two
different PCR products.
In position 4818 a transition G to A is detected. This variant is described for the first
time, is in the coding region and is a synonymous substitution, tyrosine to tyrosine
Finally a new variants is found in two different samples, it is a transition G to A in
position 4364. The 4364 G to A is in the intron two and in the overlapping region of
amplicons 4 and 5, so it was confirmed both in DHPLC and sequence in two different
PCR products.
The five different variants that we discovered were distributed in four individuals in this
manner:
One subject presents only 4818 G to A and one subject presents only 4364 G to A.
In one sample were found the –69 C to T and the 4502 C to T. In the last  positive case
were found in the meanwhile the 2392 C to G and the 4364 G to A.
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DISCUSSION
Hepcidin, the long awaited iron hormone, is the principal downregulator of the transport
of iron across the small intestine and the placenta, and its release from macrophages.
The present view is that hepcidin downregulates iron efflux from the intestine and
macrophages by binding FPN and, following complex internalisation, leads to FPN
degradation. In HFE, TfR2, and HJV related HC, hepatic expression or serum/urine
levels of HAMP are inappropriately low.42 43 53 54 Its expression in the liver is also
significantly impaired in HFE, TfR2, and HJV knockout mice24 55–57 and hepatic
deposition of iron in HFEKO animals can be prevented by hepcidin overexpression.58
These findings suggests a unifying pathogenic model for all forms of HC in which HFE,
TfR2, and HJV are all independent but complimentary regulators of hepcidin synthesis
in the liver (fig 1). Hypothetically, these three proteins may be important for sensing
circulatory iron and turning on hepcidin gene transcription, albeit with different
mechanisms and functional impact. As the central role in iron homeostasis and in
hemochromatosis disease development of this small peptide was established, we
decided to analyze the variability in the promoter and in the coding region in 84 Italian
subjects that presented symptoms of iron overload and resulted negative for the three
reported HFE  mutations. In the screening study a total of 420 amplicons were analyzed
and 5 different variants were detected. Of these 5 variants 3 were in non-coding region
and two in were found in exons, but resulted synonymous mutations.  These results
reflect a picture of high degree of conservations, especially if we consider that the
subject that entered in the study share some defects in iron metabolism pathways and
are not representative of general population. In three different studies several rare
variants in HAMP gene region are reported  as causative for hemochromatosis disease.
In our case we can not rule out a possible involvement of the variant detected in iron
overload phenotype, but it is difficult to demonstrate.  From our results we can conclude
that even though hepcidin plays a pivotal role in iron homeostasis regulations the
molecular variability of the HAMP gene give only a marginal contribution in iron
overload phenotypes.
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CHAPTER 2
MOLECULAR VARIABILITY IN THE CHROMOSOMIC REGION OF
HAPTOGLOBIN GENE
INTRODUCTION
Haptoglobin (Hp) is a plasma protein with hemoglobin-binding capacity. It is a well-
known marker of hemolysis. Hp is also an acute-phase protein that functions as a
bacteriostatic agent, an inhibitor of prostaglandin synthesis and angiogenesis [1].
However, the best-known biological function of Hp is capture of hemoglobin (Hb).
After destruction of erythrocytes, free Hb in the circulation passes through the
glomerular filter and renal damage may occur. The binding of Hp with Hb prevents both
iron loss and kidney damage during intravascular hemolysis [2].
The identification of functional differences in haptoglobin molecules resulting from
relatively common polymorphisms has further elucidated the importance of haptoglobin
in iron homeostasis and in disease processes influenced by iron metabolism including
hemochromatosis atherosclerosis and cardiovascular disease, and infectious diseases.
HAPTOGLOBIN POLYMORPHISMS AND DIFFERENCE IN PROPERTIES
BETWEEN THE PHENOTYPES
Haptoglobin (Hp) is an ?2-sialoglycoprotein with hemoglobin (Hb)-binding capacity [3
and 4] and is characterized by a molecular heterogeneity with three major genotypes:
Hp 1-1, Hp 2-1 and Hp 2-2 [2, 3, 4 and 5].
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These genotypes are molecularly determined by two alleles: Hp1 and Hp2 [3 and 4].
The homozygote, Hp1/Hp1 shows a single fast-migrating Hp 1-1 protein band on starch
gel electrophoresis. The homozygote Hp2/Hp2 shows a series of slower migrating
bands. The heterozygote Hp1/Hp2 displays another series of slow bands and a weak Hp
1-1 band. Hp consists of two different polypeptide chains, the ?-chain and the ?-chain
[3 and 4]. The ?-chain (40 kDa) is heavier than the ?-chain and is identical in all Hp
types. The ?-chain shows three major forms: ?-1s, ?-1f (s=slower, F=faster) and the
slow migrating ?-2-chain. The Hp 1-1 phenotype has ?-1-chains, while ?-2-chains are
present in Hp from individuals with the Hp 2-1 or Hp 2-2 phenotype [3 and 4]. The loci
involved for the Hp synthesis are located on chromosome 16q22. The Hp 1-1 protein is
a small molecule (86 kDa) with formula (?1?)2. Heterozygote Hp 2-1, (?1?)2+( ?2?)n
(n=0, 1, 2,…), is characterized by polymerization. Hp 2-2 comprises higher molecular
mass forms (>200 kDa) with formula (?2?)n (n=3, 4, 5,…) [5 and 7] .
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The principal difference between alleles Hp 1 and Hp 2 is the presence of a duplicated
DNA segment of 1700 bp in Hp 2 but not Hp 1 (2). Most likely, formation of the Hp 2
allele is the result of a breakage and reunion event at non-homologous positions within
the fourth and second introns of two Hp 1 genes. As a consequence of this illegitimate
crossing-over event, exons 5 and 6 of allele Hp 2 originate from exons 3 and 4,
respectively, of one of these Hp 1 genes
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Fig. 1.
Iconographic presentation of the differences in molecular weight between the different
haptoglobin phenotypes.
The synthesis of Hp is considerably lower in fetal than in adult liver [3]. The hepatic
synthesis of Hp is induced by cytokines such as interleukin-6, interleukin-1 and tumor
necrosis factor [3 and 8]. The haptoglobin concentration is Hp phenotype-dependent.
The reference range for haptoglobin concentration is lower in individuals carrying the
Hp 2-2 phenotype than individuals carrying the Hp 1-1 and Hp 2-1 phenotype [9].
The haptoglobin phenotype distribution differs according to geographical localisation of
the population studied [1]. The haptoglobin allele frequencies show marked
geographical differences, with the lowest Hp1 allele frequency (0.10) in Southeast Asia
and the greatest Hp1 frequency (0.80) in indigenous populations of South America [1].
The phenotypic distribution in European populations shows that 15% individuals are Hp
1-1, 50% Hp 2-1, and 35% Hp 2-2, corresponding with a Hp1 allele frequency of 0.40
[1 and 10]
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Haptoglobin polymorphisms, directly or indirectly, influence pathways involved in iron
metabolism:
Hp forms a soluble complex with Hb. The binding of Hp with Hb is the strongest
known noncovalent interaction among the plasma transport proteins, with the complex
having a very high affinity and stability [11]. Circulating Hp is saturated when
500–1500 mg/l free Hb is present.
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The half-life of Hb–Hp complexes in plasma is 20 min [12]. Hepatocellular uptake of
Hp–Hb complexes reduces the loss of haem iron through the kidney [1]. Unlike
hemopexin and transferrin, Hp is not recycled after endocytosis but the Hb–Hp complex
is instead degraded by lysosomes [13]. Hb binding depends not only on the serum
concentration of Hp but also on the Hp phenotype [14]. The hemoglobin binding
capacity is lowest among Hp 2-2 subjects [15] due to lower serum concentrations, as
discussed above, as well as to a lower ability to bind Hb [11]. After destruction of
erythrocytes, free Hb in the circulation passes through the glomerular filter and renal
damage may occur. Hp reduces the loss of Hb and iron, because the Hb–Hp complex is
not filtered through the glomeruli but is transported to the liver. The lower binding
capacity of Hb in individuals with the Hp 2-2 phenotype results in more renal damage
and higher serum iron levels [1].
Free Hb promotes the accumulation of hydroxyl radicals [16] and harmful reactive
oxygen species (free radicals), because iron (Fe2+) can generate extremely reactive
hydroxyl radicals in the presence of H2O2 (Fenton reaction). Haem iron catalyses the
oxidation of low-density lipoproteins, which can damage vascular endothelial cells [17].
In addition, the breakdown of erythrocytes in the interstitial fluid results in Hb-mediated
hydroxyl radical formation. Plasma Hp can be regarded as a major antioxidant
protecting against Hb-driven lipid peroxidation [18 and 19]. The ability of haptoglobin
to reduce hemoglobin-induced free radical damage is phenotype-dependent [14 and 18].
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The distribution of highly polymeric Hp 2-2 proteins in extravascular fluids is restricted
by their molecular mass [5]. Consequently, the antioxidative capacity of body fluids is
less effective in Hp 2-2 individuals [5].
An increased frequency of Hp 2-2 and Hp0 was observed in familial and posttraumatic
epilepsy and was explained by a less efficient inhibition of Hb-driven brain-lipid
peroxidation after hemorrhage within the central nervous system [22].
CD163 has been identified as the monocyte–macrophage receptor that binds the Hb–Hp
complex. Hp and Hb do not bind to the CD163 receptor separately.
Fig. 2. Schematic outline of the Hp–Hb scavenging function of CD163/HbSR. It is feasible to envision that binding of Hp–Hb by
CD163/HbSR on macrophages can lead to cross-linking. Only the Hp 1-1 phenotype is shown in the figure.
CD163 binds only hemoglobin and haptoglobin in complex, which indicates the
exposure of a receptor-binding neoepitope. In its function as a Hb scavenger, the CD163
receptor accounts for a substantial transfer of iron into the macrophages. Complexes of
hemoglobin and multimeric Hp 2-2 haptoglobin exhibit higher functional affinity for
CD163 than do complexes of hemoglobin and dimeric Hp 1-1 haptoglobin [23]. In vitro
experiments with radiolabeled (125I) Hb showed that human peripheral blood
monocytes take up Hb–Hp 2-2 complexes whereas, even in zymosan-activated
monocytes, free Hb and Hb bound to Hp 1-1 or 2-1 are not internalised [24]. When
intracellular concentrations of haem increase with the endocytosis of Hb–Hp 2-2
complexes, there is a rapid induction of ferritin synthesis. In mammals, the cytosolic
ferritins are ubiquitous and made of two subunit types, the H- and L-chains, with about
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50% sequence identity and very similar three-dimensional (3D) structures. H-chains
have ferroxidase activity, which accelerates Fe(II) oxidation, the rate-limiting step of
ferritin iron incorporation, in a reaction that consumes one dioxygen molecule per two
Fe(II) ions with the production of hydrogen peroxide. The L-subunit has no catalytic
activity on its own, but it assists the activity of the H-subunits by offering sites for iron
nucleation and mineralisation and increasing the turnover at the ferroxidase centers
[25]. Higher cytosolic L-ferritin levels are present in peripheral blood monocytes from
Hp 2-2 subjects (687±152 _g/g protein) compared to Hp 1-1 and 2-1 subjects (326±83
and 366±109 _g/g protein, respectively) [24]. This effect is presumably due to iron
released from haem affecting the iron regulatory protein (IRP) which regulates ferritin
mRNA translation by binding to the iron responsive element (IRE) [26 and 27].
Cytosolic H-ferritin content in monocytes is not different between Hp phenotypes,
similar to what is observed in iron-loaded livers where only the L-ferritin form is
upregulated [28]. In males, but not in females, the Hp 2-2 phenotype is associated with
higher serum iron, transferrin saturation and ferritin concentrations than in the Hp 1-1
and Hp 2-1 phenotype, whereas soluble transferrin concentrations are lower. Serum
ferritin correlated with monocyte L-ferritin content which is also highest in the male Hp
2-2 subgroup [24]. A positive correlation was observed between serum and monocyte
ferritin levels suggesting that increased L-ferritin synthesis in monocyte–macrophages
results in higher ferritin levels in the circulation [24].
1.2.4. Influence on the immune system
Haptoglobin has been proposed to be involved in a highly interactive ensemble of
lymphocytes, neutrophils, and monocytes participating in inflammatory processes [29,
30, 31, 32, 33 and 34]. Kristiansen et al. [23] speculated that the Hp–Hb complex, like
antibodies, may cross-link several CD163 molecules on the surface of macrophages,
triggering an internal signalling cascade that results in increased secretion of anti-
inflammatory cytokines. Human serum from Hp 2-2 and Hp 2-1 individuals
agglutinates the bacterial cells of the Streptococcus pyogenes group A strain, carrying
the T4 antigen. The Hp 2-2 serum has higher agglutination titres than the Hp 2-1 serum.
In contrast, serum from individuals with the Hp 1-1 phenotype has no agglutination
effect. Hp is not a true antibody because it does not possess the highly variable antigen-
binding sites characteristic of the Fab moiety of immunoglobulins. The agglutination is
probably mediated via binding with lectin-like structures [35 and 36].
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Comparison of reference values for lymphocyte subsets in the peripheral blood and
bone marrow show significant differences between haptoglobin phenotypes. Individuals
with the Hp 2-2 phenotype have higher peripheral B-lymphocyte counts and CD4+ T
lymphocytes counts than individuals with the Hp 1-1 phenotype. In contrast, in the bone
marrow, CD4+ T cell percentages are high but B cell percentages are low in individuals
with the Hp 2-2 phenotype. Flow cytometric analysis demonstrates that Hp binds to the
CD22 receptor on human B lymphocytes. Although the affinity of the binding is the
same for the three phenotypes, the number of free CD22 binding sites in the circulation
is estimated to be higher in Hp 2-2 individuals. No significant Hp binding has been
detected for T cells and NK cells [33].
A controversial issue is the association of increased body iron stores with increased
cardiovascular risk [43]. In this context, Hp polymorphism has been proposed as a risk
factor for developing atherosclerotic vascular disease, independent of the classical risk
factors such as smoking, hypertension, diabetes mellitus, or serum lipid concentrations.
In essential hypertension, coronary artery lesions and target organ damage are more
common among Hp 2-2 patients. It is suggested that hypertensives with a Hp 2-2
phenotype need more complex combinations of antihypertensive drugs to reduce blood
pressure than individuals with the Hp 1-1 phenotype. The hypertensive patient carrying
Hp 2-2 is more likely to accumulate atherosclerotic lesions of the coronary or peripheral
arteries, despite comparable lipid levels, smoking habits and BMI [44]. When compared
with individuals carrying the Hp 1-1 phenotype, males carrying the Hp 2-2 phenotype
are at risk for developing premature coronary artery disease [45] and peripheral vascular
disease [46]. Following acute myocardial infarction, the severity of infarction and
outcome are worse for the Hp 2-2 patients [47]. Diabetic patients who are homozygous
for the Hp1 allele are provided increased protection against the development of diabetic
vascular complications such as nephropathy and retinopathy [48 and 49]. In a recent
study, the Hp phenotype seems to be highly predictive of adverse cardiac events,
particularly myocardial infarction, in the 1-year period after percutaneous transluminal
coronary angioplasty in individuals with diabetes. Patients with the Hp 1-1 phenotype
had a 0% risk of myocardial infarction, in contrast to patients carrying the Hp 2-2
phenotype who had a risk of 8.4% (p<0.001). No difference in risk was seen in
individuals without diabetes [50]. The same authors demonstrated a severe impairment
in the ability of the Hp 2-2 phenotype to prevent oxidation by glycosylated hemoglobin.
They proposed that the specific interaction between diabetes, cardiovascular disease and
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Hp phenotype is the result of the impaired clearing capacity of glycosylated
hemoglobin–Hp complexes from the subendothelial space. A delay in the clearing of
these complexes results in oxidation of low-density lipoprotein to atherogenic oxidized
low-density lipoprotein [51].
Hp acts as a natural bacteriostat by preventing the utilisation of Hb by pathogenic
bacteria which require iron for their growth [52]. The iron-restrictive environment in
body fluids established by Hp–Hb binding is part of the nonspecific defense mechanism
against bacterial invasion. Rats inoculated intraperitoneally with pathogenic Escherichia
coli and Hb are fully protected against lethality by simultaneous administration of Hp
[52]. L. pneumophila is an intracellular pathogen which has a definite requirement for
iron, reflected by an inability to grow on medium in the absence of iron
supplementation. In vitro, intracellular multiplication in macrophages is inhibited in the
absence of iron. In a cohort of infected Dutch patients, 117 patients with Legionella
disease (LD), 95 matched controls for age, gender and residency and 61 asymptomatic
L. pneumophila seropositive controls were included. In this cohort, the Hp phenotype
did not influence susceptibility for LD. However, Hp 2-1 was associated with severe
LD, which in this cohort could not be explained by differences in iron status [53].
Clinical studies have demonstrated that Hp polymorphism may play a role in a number
of viral infections including HIV and hepatitis C [10, 54, 55 and 56]. An initial study in
HIV-1 infected adults demonstrated the Hp 2-2 phenotype was associated with: (i)
higher mortality rates; (ii) lower median survival time since diagnosis of HIV
seropositivity (Hp 2-2, 7.33; Hp 2-1/1-1, 11.0 years); (iii) higher baseline plasma HIV-1
RNA levels among antiretroviral drugs-naïve subjects (Hp 2-2, 5.26±0.82; Hp 2-1,
4.64±0.73; and Hp 1-1, 3.75±1.01 log10 RNA copies/ml); (iv) the greatest increase in
plasma HIV-1 RNA levels over a 1-year period [55]; and (v) more accumulation of iron
and oxidation of vitamin C, suggesting that less efficient protection against
hemoglobin/iron-driven oxidative stress may be a direct mechanism for stimulating
viral replication. Oxidative stress induced by reactive oxygen radicals stimulates HIV
replication through the activation of the nuclear transcription factor-_B, and contributes
to the development of cell damage and immunodeficiency [56 and 57]. A more recent
case-control study revealed that Hp 2-2 was associated with significantly lower CD4+
levels among HIV-1-infected subjects in Ghana [58]. The Hp0 phenotype has been
identified as a protective factor in HIV-1 seropositive Ghanaians [59].
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In liver transplant patients following chronic hepatitis C infection, graft survival was
shown to be dependent on donor Hp phenotype, Hp 2-2 being associated with lowest
graft survival [60].
Although conflicting data are available, the haptoglobin polymorphism seems to
influence iron recycling in healthy men and patients with hereditary hemochromatosis.
This is demonstrated by the CD163 receptor mediated mechanism through which
hemoglobin–Hp complexes are internalised by monocyte–macrophages. The uptake of
hemoglobin–Hp complexed by the CD163 receptor is more potent for the
hemoglobin–Hp 2-2 complex than for the complex carrying the Hp 1-1 phenotype. In
addition, more evidence has become available demonstrating the deleterious effect of
the Hp 2-2 phenotype in diabetic patients and the evolution toward complications of
atherosclerotic processes. The haptoglobin polymorphism clearly influences outcome in
the host after viral and bacterial infection. Differences in clinical presentation in patients
with iron storage disease, atherosclerotic processes, and infections are explained, in
part, by the different properties of the haptoglobin pheno/genotypes.
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HAPTOGLOBIN AND MALARIA
In malaria-endemic countries of Africa, anaemia is very common in pregnant women
and in children under five. Although anaemia is multifactorial—causative factors
include iron deficiency and other nutritional deficiencies, helminth infection, and
HIV—malaria is clearly an extremely important factor. Over half of malaria-related
deaths are attributed to severe malaria anaemia (which is defined as malaria
parasitaemia and a haemoglobin (Hb) concentration less than 50 g/l) [1]. Several
antimalarial interventions have been shown to prevent anaemia, including insecticide
treated nets, residual spraying, malaria chemoprophylaxis, and, more recently,
intermittent presumptive treatment of infants (i. e., antimalarials coadministered with
childhood immunization). Insecticide-treated nets have been shown to decrease all-
cause mortality [2]. The pathogenesis of malaria anaemia remains incompletely
understood. Dyserythropoiesis (disordered red cell development, which is, at least in
part, due to inflammatory cytokines acting on erythroid precursors), intravascular
hemolysis of infected red cells, and destruction of both parasitized and uninfected
erythrocytes by splenic macrophages are all important [3,4]. Interestingly, it has been
estimated that ten or more uninfected erythrocytes may be lost for each infected one [5],
presumably because malaria infection alters uninfected erythrocytes. The probable
causes of red cell loss include oxidation of band 3 (the anion transporter of the
erythrocyte membrane) or membrane lipids, and deposition of IgG, complement, or
immune complexes on the erythrocyte surface. Hp2-2 is less able than Hp1-1 to
penetrate extravascular spaces, and Hp2-2 is less able to prevent oxidative damage or
immune activation than the other phenotypes [7].
Given the importance of intravascular hemolysis in malaria infection, studies of Hp in
malaria are important, but results to date have been inconclusive. Earlier studies based
on phenotyping suggested Hp1-1 was associated with severe or symptomatic infection
[8,9]. For example, in one study of 72 patients in Sudan with cerebral malaria, the
percentage of patients with Hp phenotypes 1-1, 2-1, and 2-2 were 63.9%, 29.2%, and
6.9%, respectively [8]. But the low prevalence of Hp2-2 and the high prevalence of
Hp1-1 in the patients in this study may reflect lack of sensitivity of the electrophoretic
technique used in the study to detect the less abundant (and multiple) bands of Hp2-2
rather than the single abundant Hp1-1. Circulating levels of Hp1-1 are
normally significantly higher than those of Hp2-2, but levels fall during malaria
infection due to clearance of Hp/Hb complexes; age may influence the degree of fall in
61
Hp with malaria [10]. More recently, PCR-based genotyping studies have examined
associations between Hp genotype and severe malaria or associations between Hp
genotype and mild disease [11,12]. These studies did not find clear associations with Hp
genotype; although, in one study, there was a suggestion of an association with severe
malaria, especially severe anaemia. In a recent study Atkinson and colleagues have
taken a different approach [13]. Working in The Gambia, where malaria transmission is
intense but highly seasonal and anaemia is a common complication, they followed a
group of children over the malaria season. The authors used Hb concentration as their
main readout. Although baseline Hb levels were similar across Hp genotypes, children
who were Hp2/2 had a greater fall in Hb (by 4 g/l) over the malaria season than did
other children. Hp genotype significantly predicted Hb levels at the end of the malaria
season in multivariate analysis, together with iron status and several other variables. A
separate analysis examining factors influencing the magnitude of the fall in Hb gave
similar results. Additionally, children with Hp2/2 genotype were more likely to be
parasitaemic. The authors suggest that the effect of Hp genotype on the fall in Hb (and,
thus, possible protection from anaemia) may be more significant than that of sickle cell
trait (HbAS) or glucose-6-phosphate dehydrogenase deficiency. On the other hand,
sickle cell trait and glucose- 6-phosphate dehydrogenase deficiency have been more
compellingly associated with protection from severe malaria than have Hp genotypes
[14]. How Does Hp Affect Hb Levels? How does Hp genotype influence Hb fall? The
authors offer several interesting suggestions. Because destruction of uninfected
erythrocytes may be especially important in development of malaria anaemia, this
mechanism is one plausible route. Oxidative damage to uninfected cells might be more
marked in Hp2-2 individuals since Hp2-2 proteins bind less efficiently to Hb, and since
levels of Hp2-2 are lower and more easily depleted, increasing premature destruction of
erythrocytes. Another reason Hp genotype may influence Hb levels might be because
complexes of Hp2-2 with Hb, but not other Hp/Hb complexes, enter monocytes (which
express less CD163 than macrophages), stimulating cytokine release by these
circulating cells. Thus, different Hp types inducing different cytokine responses may
affect the duration of inflammatory, marrow-suppressive cytokine production following
malaria. Persistent marrow suppression, as judged by inappropriately low reticulocyte
responses after resolution of infection, is a feature of malaria [3,4]. And Hp2/2 genotype
has been associated with increased iron accumulation in haemochromatosis— in one
study but not in others (reviewed in [7])—suggesting Hp genotype may have some role
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in iron homeostasis. Interestingly, the 17% prevalence of Hp2/2 in Atkinson and
colleagues’ study was much lower than that which was reported in European
populations [7], suggesting a possible protective role for Hp1 genotypes against malaria.
Public Health Implications Is a 4 g/l difference in Hb fall clinically relevant? Probably.
Although the effects of this fall on the proportion of children suffering moderate or
severe anaemia are not given in the study, the population distribution of Hb levels is
wide. A fall in mean Hb may translate into increased numbers of individuals with
symptomatic disease, although this effect is not demonstrated in this study. From a
public health perspective, interventions that result in a rise in Hb of similar
magnitude—such as intermittent presumptive treatment in pregnancy [15]—are
endorsed by the World Health Organization. And small changes in group levels may
hide subgroups with more dramatic changes in Hb. How one might identify individuals
at risk for the more dramatic falls in Hb, or whether antimalarial measures would
prevent such falls, are unresolved questions.
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HEREDITARY HEMOCHROMATOSIS
The phenotypic expression of hereditary hemochromatosis associated with the
Cys282Tyr mutation of the HFE gene, varies from a fully penetrant clinical syndrome
characterised by bronze pigmentation, cirrhosis, arthritis, endocrinopathy and
cardiomyopathy to a mere laboratory finding of increased serum iron status [37]. This
phenotypic heterogeneity could be influenced by additional non-genetic
(environmental) causes, additional mutations or additional genes. The Hp gene has been
proposed as one of the modifier genes in the phenotypic expression of HFE-linked
hemochromatosis [38].
Three studies have examined the possible influence of the Hp gene on the phenotypic
expression of HFE-linked hereditary hemochromatosis. In one study of 167 Cys282Tyr
homozygous patients, identified as having hereditary hemochromatosis by clinical
symptoms, a low Hp1 allele frequency (0.30) was found due to an overrepresentation of
the Hp 2-2 type (49%), suggesting that the Hp 2-2 phenotype is associated with an
accelerated iron overload [38]. Male patients carrying Hp 2-2 had higher serum ferritin
levels (median: 1747 _g/l) than those with a Hp 1-1 or 2-1 type (median 1100 _g/l)
(p<0.03). The volume of blood removed with phlebotomy to achieve iron depletion
(defined as serum ferritin <50 _g/l) was also higher in Hp 2-2 patients (p<0.03) [38].
Two other studies have not shown an association [39 and 40]. Beutler et al. [40] found
no overrepresentation of the Hp 2-2 phenotype in 115 hemochromatosis patients and the
Hp polymorphism did not influence the iron status of patients and 117 healthy subjects.
Carter et al. [39] found no influence of the Hp phenotype on transferrin saturation and
ferritin concentration in 265 randomly selected control subjects, in 66 blood donors
homozygous for the HFE Cys282Tyr mutation lacking clinical features of
hemochromatosis, and in 68 patients presenting clinically with hemochromatosis, who
were homozygous for Cys282Tyr. Both studies [39 and 40] concluded that Hp type
neither influences iron status in normal subjects nor predicts clinical presentation of
hereditary hemochromatosis in individuals from South Wales and the United States.
The difference between our study and the studies by Carter and Beutler can be
explained by: (1) the moderate effect on iron homeostasis of the haptoglobin phenotype
in comparison with the hemochromatosis gene. The rate of iron uptake through
haptoglobin–hemoglobin complexes is relatively small as compared to major iron
regulatory pathways. However, as in hemochromatosis, a long-term effect may have
important consequences on iron status. This is further supported by the finding in liver
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transplant patients, where donor Hp phenotype determines the iron status post-
transplantation [41]. (2) Differences in patient selection and populations may also
explain these contradictory findings. For example most Cys282Tyr homozygotes found
by screening [40] were asymptomatic, whereas Cys282Tyr homozygotes in our study
[38] were selected due to their clinical presentation of hemochromatosis. This is clearly
reflected by serum iron markers in these trials. In Beutler's cohort, [40] low
concentrations of serum ferritin (<100 _g/l) and serum transferrin saturation (<50%)
were observed in a large number of cases. Higher values of serum ferritin and serum
transferrin saturation in Cys282Tyr homozygous individuals were seen in our trial [38].
(3) It is possible that the conflicting results might reflect geographical differences
between study populations. It is of interest, in this regard, that no relationship between
serum iron indices and Hp phenotype could be found in reports from Africa [42]. If
these geographical differences are the consequence of differences in genetic background
o r  d i f f e r e n c e s  i n  t h e  e n v i r o n m e n t ,  i s  u n c l e a r .
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MATERIALS AND METHODS
SAMPLES
A total of 96 unrelated probands between 7 and 47 years of Italian ancestry, with serum
transferrin saturation values between 40% to 99% were selected. The probands were
previously typed for the three most prevalent mutations related to hereditary
hemochromatosis: C282Y, H63D, S65C in the Hfe gene, and resulted negative. The
patients were referred from Clinical Hematologic, Interne Medicine from S. Orsola-
Malpighi hospital of Bologna.
A total of 54 unrelated subjects were collected in Castelmassa village (Rovigo, Italiy),
along Po river, in an area that until the 1930 was characterized by pandemic malaria.
Subjects were selected by age, individuals younger than 60 years old were excluded,
this is to collect only individual that grew up when malaria was still acting in the area or
immediately after its removal.
A total of 96 unrelated healthy subject of Italian origin were included in the study and
used as control pool.
DUPLICATION GENOTYPING
DNA sequences specifying haptoglobin alleles Hp 1 and Hp 2 and the haptoglobin-
related gene. The Hp 1- and Hp 2-specific sequences are contained in the
EMBL/GenBank Data Libraries under accession numbers AC004682 and M69197,
respectively (6)(7). In these sequences, the haptoglobin gene is represented by the allele
subtypes Hp 1S and Hp 2FS (2). According to the sequence present in AC004682, the
Hp 1-specific DNA region has a length of 1711 bp (Fig. 1 ); it extends, in an inverse
orientation, from nucleotide position 188616 to nucleotide position 186906. In the
sequence present in M69197, the 3435-bp Hp 2-specific DNA segment starts at position
2804 and ends at position 6238; it contains two units of similar sequences, consisting of
1724 and 1711 bp (Fig. 1 ). The sequences of the 1711-bp segments present in
AC004682 and M69197 are complementary with the exception of one divergence
located at position 188141 in AC004682, which corresponds to position 5003 in
M69197. The sequence of the haptoglobin-related gene is also contained in M69197.
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Hp 1 is represented by subtype Hp 1S, as indicated by the presence of the 1711-bp
element. Hp 2 is represented by subtype Hp 2FS, as shown by the presence of the 1724-
bp element followed by the 1711-bp element. The arrows, representing oligonucleotide
primers A, and B are located at positions next to the binding sites of the primers within
the DNA sequence. Also shown are the sizes of the PCR products obtained with primer
pairs A/B (1757 and 3481 bp).
OLIGONUCLEOTIDE
Primers A (5'-GAGGGGAGCTTGCCTTTCCATTG-3') and B (5'-
GAGATTTTTGAGCCCTGGCTGGT-3') were used for amplification of a 1757-bp Hp
1 allele-specific sequence and a 3481-bp Hp 2 allele-specific sequence (Fig. 1 ).
In Hp 1 and Hp 2, the annealing sites for primer A are located immediately upstream of
the 1711-bp unit and the 1724-bp unit, respectively (Fig. 1 ). The nucleotide at the 5'
end of primer A corresponds to position 188639 in AC004682 (Hp 1) and position 2781
in M69197 (Hp 2). Primer B has binding sites just downstream of the 1711-bp elements
of Hp 1 and Hp 2 (Fig. 1 ). The nucleotide at the 5' end of primer B corresponds to
position 186883 in AC004682 (Hp 1) and position 6261 in M69197 (Hp 2).
The 20-?L reactions contained 2 U of Taq polymerase (Qiagen), 1–100 ng of DNA, and
200 ?M each of dATP, dCTP, dGTP, and dTTP (Invitrogen); PCR buffer was used as
suggested by the supplier (Qiagen) with no supplements added. After initial
denaturation at 95 °C for 2 min, the two-step thermocycling procedure consisted of
denaturation at 95 °C for 1 min and annealing and extension at 69 °C for 2 min (in the
presence of primers A and B or primers A, B, C, and D) or 1 min (in the presence of
primers C and D only), repeated for 35 cycles, and followed by a final extension at 72
°C for 7 min. The thermocyclers used were GeneAmp PCR systems 9600 and 9700
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(Applied Biosystems). For genotype assignments, the PCR products were separated in
0.7% agarose gels. Eight percent polyacrylamide gels (Invitrogen) were also suitable in
cases where primers C and D were used for the determination of the Hp 2 allele instead
of primers A and B. Genotype determinations were done without knowledge of the
phenotyping results.
TETRARMS
A simple and economical SNP genotyping method involving a single PCR reaction
followed by gel electrophoresis is reported here. The technique, named tetra-primer
ARMS-PCR, adopts certain principles of the tetra-primer PCR method (5) and the
amplification refractory mutation system (ARMS) (6; Fig. 1). Differences between the
tetra-primer ARMS-PCR method, the original tetra-primer PCR method and the Bi-
PASA (bidirectional PCR amplification of specific alleles) method reported by Liu et al.
(7) are summarised in Table 1. In contrast to Bi-PASA, both inner primers of the tetra-
primer ARMS-PCR method encompass a deliberate mismatch at position –2 from the
3_-terminus. An extra destabilizing mismatch has been found to increase the specificity
of classical ARMS-PCR (6,8–11). Rules for selecting a nucleotide for the additional
mismatch in classical ARMS PCR have been described previously (8): a ‘strong’
mismatch (G/A or C/T mismatches) at the 3_-terminus of an allele-specific primer will
likely require a ‘weak’ second mismatch (C/A or G/T) and vice versa, whereas a
‘medium’ mismatch (A/A, C/C, G/G or T/T) at the 3_-terminus will likely require a
‘medium’ second mismatch.
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Schematic presentation of the tetra-primer ARMS-PCR method. The single nucleotide polymorphism
used here as an example is a G_A substitution, but the method can be used to type other types of single
base substitutions. Two allele-specific amplicons are generated using two pairs of primers, one pair
(indicated by pink and red arrows, respectively) producing an amplicon representing the G allele and the
other pair (indicated by indigo and blue arrows, respectively) producing an amplicon representing the A
allele. Allele specificity is conferred by a mismatch between the 3_-terminal base of an inner primer and
the template. To enhance allelic specificity, a second deliberate mismatch (indicated by an asterisk) at
position –2 from the 3_-terminus is also incorporated in the inner primers. The primers are 26 nt or
longer, so as to minimize the difference in stability of primers annealed to the target and non-target
alleles, ensuring that allele specificity results from differences in extension rate, rather than hybridisation
rate. By positioning the two outer primers at different distances from the polymorphic nucleotide, the two
allele-specific amplicons differ in length, allowing them to be discriminated by gel electrophoresis.
It is also demonstrated here that high genotyping throughput can be achieved by
combining this method with the microplate array diagonal gel electrophoresis
(MADGE) technique (12). As primer design is a critical part of this method and is time
consuming, we have developed a primer design computer program and made it
accessible to other users through the Internet.
Computer software to design primers for tetra-primer ARMS-PCR
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As primer design is a critical part of this method and is time-consuming, we developed
a primer design computer program to facilitate this task. The program, outlined in
F i g u r e  6 ,  i s  a c c e s s i b l e  t h r o u g h  t h e  I n t e r n e t  a t
http://cedar.genetics.soton.ac.uk/public_html/primer1.html. Users need to input the
target DNA sequence, specify the polymorphic site and define criteria for the primers
(Tm, %GC, length and complementarity) and product sizes.
PROMOTER RESEQUENCING.
We performed PCR amplification to determine HP genotypes and the presence of the
HP*del allele, as described previously (Koda et al. 1998, 2000). We also examined
HP*1 variants by amplifying HP exons 2 to 4 (Koda et al. 1998). Using restriction
digests with XbaI, we were able to differentiate the HP*1S and HP*1F alleles (Maeda et
al. 1984). The promoter region of HP was amplified using PCR, purified, and sequenced
directly with an ABI Prism dye terminator cycle sequencing ready reaction kit (Applied
Biosystems, Tokyo, Japan).
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PRELIMINARY RESULTS
HP PROMOTER RESEQUENCING IN A WORLDWIDE POPULATION
We evaluated the distribution of HP alleles and base substitutions at the promoter region
among Africans (Ghana), Europeans (South Africa), and Chinese to determine the
population differences and associations. The distribution of the four HP alleles among
the study populations showed marked geographic differences (Table 1). The HP*2
allele was the most prevalent in all three populations but was significantly higher in the
Chinese population (P 0.01). The HP*1F allele was absent from the Chinese population
and was high in the African population (P 0.02). The HP*1S allele was low in the
African population (P 0.005). The HP*del allele was present only in the Chinese
population, as observed previously (Koda et al. 2000). All genotype distributions were
in Hardy-Weinberg equilibrium. There was distinct variation in the distribution of HP
promoter SNPs ( 55AVG,  61AVC,  101CVG,  104TVA,  191TVG, and  242CVT)
across the study populations.
Strikingly, the  61C and  101G substitutions were found only in the African population
(Table 2). The  242T substitution was generally high in Europeans (P 0.01). The  55G
substitution was predominant in all populations but was elevated in Africans compared
to the Chinese population (P 0.007). The  104A substitution was significantly high in
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Africans. These observations reveal that four SNPs ( 55G,  61C,  101G,  104A)
occurred significantly in the African population and that the  242T mutation was
significant in the Europeans. SNPs occurred less frequently in the Chinese population.
FST estimates suggest that the African population is moderately differentiated from the
Chinese and Europeans, who appear less differentiated from each other (Table 2).
Analysis of the SNPs with the SNPs of two out-groups (chimpanzee and rhesus
monkey) showed that  55A,  61A, 101C,  104T,  191T, and  242C are the ancestral
nucleotides and that the HP promoter region is highly conserved (data not shown). The
most likely haplotypes determined by Arlequin software are shown in. We found that
the  61C and  101G substitutions were strongly in linkage disequilibrium with the HP*2
and HP*1S alleles, respectively. The  55G and  104A substitutions are almost always
associated with the HP*1F allele in both the African and European populations. The
55G substitution was found associated with HP*2 in all populations, with frequencies
that varied extensively according to the population. The  55G,  104A, HP*2 haplotype
was found only in the African population, which also had a high frequency of the  55G,
104A, HP*1F haplotype. Overall, 18 haplotypes were observed among the study
populations. Of this number, only three haplotypes were shared among all three
populations. With the exception of the  55G, HP*2 haplotype, all the shared haplotypes
were of the wild-type allele, and even then visible variations existed between the
frequency distributions.
HP DUPLICATION ALLELE GENOTYPING IN CASTELMASSA POPULATION.
The haptoglobin genotypes of 249 consecutive patients were determined with genomic
DNA prepared from blood samples. With PCR protocol 1, we successfully genotyped
244 of the 249 samples, whereas we could not establish the genotype of 5 samples. In
these five cases, the 1757-bp Hp 1-specific product was present as a relatively weak
band, probably because of low concentrations of genomic DNA.
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In the same lanes, the 3481-bp Hp 2-specific band was not visible, and it was unclear
whether individual samples did not contain the Hp 2 allele or whether the 3481-bp
product was present at concentrations too low to be detected in the gel. Thus, in these
cases, it was not possible to decide whether the genotype was Hp 1-1 or Hp 2-1.
Subsequent genotyping of the five samples with PCR protocols 2 and 3 independently
demonstrated that two samples were Hp 1-1 and three samples were Hp 2-1.
GENOTYPING OF 9 TAGSNPS IN THE GENOMIC REGION OF HP GENE
We reconstructed haplotypes for all three genes, using the PLEM algorithm (52)
implemented in the tagSNPs program (53), and selected tagSNPs on the basis of the R2
coefficient, which quantifies how well the tagSNP haplotypes predict the SNPs or the
number of copies of haplotypes an individual carries. We chose tagSNPs so that
common SNP genotypes (minor allele frequency 0.03) and common haplotypes
(frequency 0.03) were predicted with R2  0.8 (54). In order to evaluate our tagSNPs'
performance in capturing unobserved SNPs within the genes and to assess whether we
needed a denser set of markers, we performed a SNP-dropping analysis (25,55). In
brief, each of the genotyped SNPs was dropped in turn and tagSNPs were selected from
the remaining SNPs so that their haplotypes predicted the remaining SNPs with an R2
value of 0.85. We then estimated how well the tagSNP haplotypes of the remaining
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SNPs predicted the dropped SNP, an evaluation that can provide an unbiased and
accurate estimate of tagSNP performance (25,55).
TAGSNPS GENOTYPING
A simple and economical SNP genotyping method involving a single PCR reaction
followed by gel electrophoresis is reported here. The technique, named tetra-primer
ARMS-PCR, adopts certain principles of the tetra-primer PCR method (5) and the
amplification refractory mutation system (ARMS) (6; Fig. 1). Differences between the
tetra-primer ARMS-PCR method, the original tetra-primer PCR method and the Bi-
PASA (bidirectional PCR amplification of specific alleles) method reported by Liu et al.
(7) are summarised in Table 1. In contrast to Bi-PASA, both inner primers of the tetra-
primer ARMS-PCR method encompass a deliberate mismatch at position –2 from the
3_-terminus. An extra destabilizing mismatch has been found to increase the specificity
of classical ARMS-PCR (6,8–11). Rules for selecting a nucleotide for the additional
mismatch in classical ARMS PCR have been described previously (8): a ‘strong’
mismatch (G/A or C/T mismatches) at the 3_-terminus of an allele-specific primer will
likely require a ‘weak’ second mismatch (C/A or G/T) and vice versa, whereas a
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‘medium’ mismatch (A/A, C/C, G/G or T/T) at the 3_-terminus will likely require a
‘medium’ second mismatch.
rs2288000
rs11641424
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DISCUSSION
The present data suggest that HP promoter polymorphism can be used as a marker in
human population genetic studies. We determined the frequency distribution of HP
alleles and promoter polymorphism using PCR and direct DNA sequencing of PCR
products. We sequenced a 300-bp genomic DNA fragment of the HP promoter region
and found population specificity of the distribution of not only the HP alleles but also
the base substitutions at the promoter region and the haplotypes.
The  61C and  101G substitutions appear to be specific to individuals of African origin,
because they were not detected in Europeans or Asians. Interestingly, the  61C
substitution, located in one of three interleukin 6 responsive elements (Oliviero and
Cortese 1989), was also found in African Americans, with the HP 2,1mod phenotype
having a lower serum Hp level (Maeda 1991).
We have also seen this substitution in South African Xhosas at frequencies that are
similar to those observed in Ghanaians (results not shown). We previously reported that
the  61AVC and  101CVG substitutions were strongly associated with
ahaptoglobinemia and hypohaptoglobinemia, respectively, which are frequent in
African populations (Teye et al. 2003). The uniqueness of the  61C and 101G
substitutions in the African population is highlighted by the fact that they are associated
with the HP*2 and HP*1S alleles, respectively. The  104A substitution also appeared to
be specific to African populations because we detected only one (1%) allele out of 100
European alleles, whereas the Ghanaian population had as many as 92 (37.4%) out of
246 alleles and the Chinese population had none. The South African white population is
estimated to be 93% European and 7% non-European (a mix of people of southern
African and Asian descent) (Botha et al. 1975). Therefore the probability of the one
104A substitution coming from an African gene cannot be excluded. The European
population showed a higher frequency of the  242T substitution, which was the only
major marker for this population. The  55G and  191G substitutions occurred at high
and low frequencies, respectively, in all study populations, so they may not be suitable
for population genetic studies. However, the  61C,  101G,  104A, and  242T
substitutions could be useful for population genetic studies in African and European
populations.
The Chinese population appears to be less polymorphic with respect to the SNPs than
the African or European populations. However, the presence of the HP*del allele and
the absence of the HP*1F allele serve as unique markers within the Chinese population.
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The data revealed a dense SNP map within the HP promoter region, containing as many
as six polymorphic sites within a short fragment of 300 bp. Thus, together with other
markers, HP polymorphism at the allele and promoter levels may provide new pieces to
the anthropogenetic puzzle of human migration and population differentiation. All the
substitutions can be detected in a single PCR and sequencing reaction because the DNA
fragment is less than 400 bp, making it simple and convenient to analyze.
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CHAPTER 3
DOES CULTURAL ISOLATION LEAD TO INCREASED POWER IN GENE
FINDING IN ASSOCIATION STUDIES? THE BASQUE LESSON.
INTRODUCTION
Complex diseases, supposed to be caused by the interaction between multiple genes and
environmental factors, are the major public health problems in developed societies. The
recent breakthroughs in highthroughput genotyping technologies are rendering feasible
whole genome association studies, in which the whole genome is scanned for regions
where a variant modifying susceptibility to the disease may lie. This approach is based
on the ability to capture an association signal by means of the underlying linkage
disequilibrium (LD) between the genotyped polymorphism and the susceptibility
variants. Increased linkage disequilibrium would mean, thus, and increased statistical
power to capture such signals. However, whole genome association studies may be
particularly prone to the problems that have plagued association studies, affecting
reproducibility. Some of those problems are population substructure, which creates
spurious genetic associations, and the heterogeneity in the causal variants .
It has often been suggested that genetically isolated populations would offer increased
stastical power to detect association because of the impact on their genomic structure of
their particular demography. LD would be higher than in other populations because of
the reduced effective population size, which limits the opportunity for recombination to
act and erode LD. Moreover, such populations are not expected to present internal
substructure (thus reducing its impact in creating spurious associations), and to be
genetically more homogeneous, which may translate into being less diverse in the
genetic architecture of susceptibility to a particular complex disease.
While many populations have been proposed as isolated and ideal for association
studies, empirical data that verify the assumptions mentioned above are scarce. Some
studies used microsatellites in the X chromosome and found increased LD in the Saami
for northern Scandinavia (lavori di Laan & Paabo), although it is unclear how LD can
be compared between microsatellites and the now much more popular single nucleotide
polymorphisms (SNPs), given their widely different mutation rates and models. The
most comprehensive SNP-based study of LD and genetic heterogeneity on an isolated
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population was performed on the Miconesian Kosrae, where indeed heterogenity was
decreased and LD decayed more slowly with physical distance (ref.). However, to the
best of our knowledge no such study has been performed on an isolated European
population.
A candidate to being a genetically isolated population suitable for associated studies are
the Basques. They live in a small area straddling the westernmost section of the French-
Spanish border; Basques are ~1 million, of which a quarter are native speakers of the
Basque language, an isolated, non-Indoeuropean tongue. Besides the language, many
other cultural traits contribute to their cultural isolation. As for genetic isolation, they
have been described as the most differentiated population in continental western Europe
based on classical polymorphisms (i.e., blood groups, enzyme polymorphims, and
HLA) (Calafell and Bertranpetit, 1994). Their mtDNA sequences and Y-chromosome
polymorphisms do not show such relatively intense differences, and locate them at the
extreme of European-wide gradients in lineage frequencies (Bertranpetit et al., 1995;
Rosser et al., 2000; Bosch et al., 2001), and, in some Mendelian diseases, present
reduced mutation spectra with private mutations (Cobo et al. 2005)
In the present study, we seek to verify whether the clear cultural isolation of the
Basques translated into the genetic features that would make them more appropriate
than other populations for association studies, namely, reduced genetic heterogeneity
and extended LD. For that, we genotyped 123 SNPs in a ~1-Mb gene-free region of
chromosome 22 in two Basque populations, as well as in three other non-isolated
Spanish populations, which served as controls. Additionally, this data set can be used to
explore the genetic heterogeneity of Spanish populations; since a major source of
heterogeneity might be the the different contribution of the North African populations (a
varying proportion of the Iberian Peninsula was ruled by North African Moslems from
711 AD to 1492), we also genotyped three North African populations.
Our results seem to indicate that the main (and almost only) source of genetic
differentiation in our samples was Iberia vs. North Africa: the former, and the Basques
in particular, were not significantly different from each other. LD decay was not
increased in Basques either.
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MATERIAL AND METHODS
SAMPLES
We genotyped a total of 541 individuals from eight populations (Table 1): Basques from
Iparralde (the part of the Basque country lying in France) (BAF), Basques from
Gipuzkoa (a province of Spain) (BAS), Catalans (in NE Iberia) (CAT), Extremadura in
SW Spain (EXT), Andalusians in S Spain (AND), North Moroccans (NMO) and South
Moroccans (SMO), both mostly Berber-Speakers, and Sahrauis (SAH), that is, Arabs
from the Western Sahara, a former Spanish colony south of Morocco, now claimed by
this country. All individuals were autochthonous and had all four grandparents born in
the same region.
SNP SELECTION AND GENOTYPING.
SNPs were selected and genotyped as in González-Neira et al. (2006). Briefly, SNPs
were selected from dbSNP build 115 in a region spanning 987,872 bp in chromosome
22, from bp 32600114 to bp 33587986 (NCBI Build 34). The 1-Mb region begins at the
3' end of the Glycosyltransferase-like protein LARGE, which belongs to the
Glycosyltransferase family 8; no other known gene maps to this interval. Different
classes of repeats have been found in the region, including SINEs, LINEs, LTRs, STRs,
and others (Dunham et al. 1999 ).
Genotypes were produced with Spectrotyper (Sequenom), at a multiplex level of four.
Initially, 211 assays were designed. Of those, 65 had call rates <70% and were dropped,
as were six that failed Hardy-Weinberg equilibrium (HWE). The HWE cut off was
established considering that, in a given locus, the number of populations that would fail
HW follows a Poisson distribution. As the total number of tests with P < 0.05 gave an
average of 4.8 populations with P < 0.05 per locus, we excluded SNPs that were not in
HW equilibrium in a number of populations over the 95% tail of the Poisson
distribution (in this case, four populations). Finally, 14 SNPs were rejected since they
resulted monomorphic in all samples.  In total, 123 SNPs were considered in the
analysis dataset, with a final average distance between contiguous SNPs of 8060 bp.
[non torna: 211-65-6-14=126, non 123 (???)]
For the considered loci, 27 genotype discrepancies for specific SNPs in specific
individuals were found in 16,704 duplicated genotypes (0.16%), and these results were
discarded before the analysis. [in questo dataset, o in quello mondiale di González-
Neira 2006?]
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STATISTICAL ANALYSIS
Genotypic data were managed with the SNPator platform (Morcillo et al., in
preparation; www.snpator.org). SNPator allows easy database building starting from an
excel sheet and provides a friendly-use filter system for data management and analysis.
It directly performs several statistical analysis and generate input files ready-to-use for
different statistical analysis software.
  Average heterozigosities and the average number of alleles was directly calculated
us ing  the  Ar lequin  package  ver  2 .00  (Schneider ,  1996;
http://anthropologie.unige.ch/arlequin/). Arlequin was also used to compute FST
distances among populations. The FST distance matrix was visulazed by means of
multidimensional scaling (MDS) computed with Statistica ver 6.0. MDS plots in two
dimension the data points (in this case, populations) which coordinates that minimize
the difference between the distances among populations in the plot compared to those in
the input matrix. Such differences are measured with the stress parameter, which
provides a measure of the quality of the representation. MDS is considered acceptable if
the stress is less than 0.15. Since FST distances, as computed by Arlequin, can take
negative values, we scaled the distance matrix by adding a small positive number to
every value in the matrix.
The significance of the differences in allele frequencies among populations or among
groups of populations was tested by means of the analysis of the molecular variance
(AMOVA, Excoffier et al. 1992), which is also implemented in Arlequin.
 Genetic substructure within samples was investigated with a model-based clustering
method developed by Pritchard et Al.(Pritchard JK, Stephens M, Donnelly P. Inference
of population structure using multilocus genotype data. Genetics. 2000 Jun;155(2):945-
59. PMID: 10835412 [PubMed - indexed for MEDLINE]) based on a Bayesian
statistical approach. This method infers the presence of population structure from
multilocus molecular datasets attributing individuals to K arbitrary, unknown ancestral
populations. In our analysis we considered our set of data under an admixture model.
 LD decay was described by counting the proportion of SNP pairs that had r2 or |D’|
values ? 0.8 for different bins of physical distance. LD parameters were computed with
Haploview, which was also used to find tagSNPs by means of the tagger algorithm
(ref.).
RESULTS
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We obtained and analyzed genotype frequencies for 123 SNPs in a ~1-Mb geneless
region of chromosome 22 with a mean distance of 8232 bp from each other. Genotypes
were available for 541 individuals from: two Basque populations, three general Iberian
populations and three north African populations.
Mean heterozigosity plotted for each population in Fig. 1. Two conclusions can
be readily drawn: confidence intervals widely overlap, and so differences in
heterozygosty among these populations are not statiscally significant, but, in any case,
Basques are not the most genetically homogeneous population in the study. This pattern
is repeated when considering the mean number of alleles per locus (Fig. 2).
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FST genetic distances were computed among populations and plotted by means
of MDS. Since it can be argued that LD implies that SNPs do not behave as independent
variables, we performed this analysis both with the whole 123-SNP dataset, or with the
set of the 56 SNPs that were tagSNPs in each of the eight populations. Both data sets
produced very similar results, and only the latter is presented in Fig. 3. Stress was
0.0072, which is quite low and indicates a good fit between the plot and the initial
matrix. Two features stand out from the MDS plot: the main source of genetic variation
in our sample seems to be Iberian vs. North African populations, and the Basques
cluster together with the other Iberian populations. Actually, it is the small Extremadura
sample that seems to depart from the general Iberian cluster. Southern Iberian
populations would be expected to be closer to Northern Africans than any other
Iberians, if the North African invasion of 711 AD had a significant demographical
impact. However, as seen in Fig. 3, this is not the case.
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Next, we tested for the significance of the genetic differences apparent in the FST
matrix by means of AMOVA (Tab. 2). As above, we used the whole data set or the set
of tagSNPs, with very similar results. FST among all populations is 1.03% (p<0.001),
and FSC (that is, the proportion of the total genetic variance explained by differences
between groups of populations) is 2.05% (p=0.02) among the Iberians and North
Africans. FSC was much smaller among Basques and Iberian non-Basques is -0.02%,
which has to be taken as 0. That is, allele frequencies for 123 SNPs show on average no
statistically significant difference among Basques and non-Basques.
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Population substructure was investigated by means of the Bayesian approach
implemented in the STRUCTURE program. When we tested all 123 SNPs with K=2 or
K=3 populations, no clear pattern could be seen (Fig. 4,5), which is a direct
consequence of the low, albeit significant, level of differentiation between Iberian and
North African populations. However, if we selected the 14 SNPs with overall FST > 5%,
then a slight but discernible structure emerged separating Iberia from N Africa. We can
also plot the average probability per actual population of belonging to each theoretical
ancestral population (Fig. 6). In this simplified representation, the patterns described
above are clearer. In particular, we can observe that in graphs with K=3, the averages
123 SNPs 56 SNPs (tagSNPs in all pop)
Within
population
Between pop
Within groups
Among
groups
Within
population
Between pop
Within groups
Among groups
Basque_Fr, Basque_Es,
Catalan, Extremadura,
Andalucia,
North_Mor, Saharaui,
South_Mor.
98.97 % 1.03  %  P 0.00 98.97 % 1.03  %  P 0.00
North_Mor, Saharaui,
South_Mor.
100.13 % -0.13 % P 0.7 100.14 % -0.14 % P 0.7
Basque_Fr, Basque_Es,
Catalan, Extremadura,
Andalucia.
100.13 % -0.13 % P 0.71 100.02 % -0.02 % P 0.38
Basque_Fr, Basque_Es,
Catalan, Extremadura,
Andalucia /
North_Mor, Saharaui,
South_Mor.
98.09 % -0.13 %  P 0.79 2.05 % 98.30 % -0.07 %  P 0.58 1.77 %
Basque_Fr, Basque_Es /
Catalan, Extremadura,
Andalucia.
100.13 % -0.12 %  P 0.63 -0.02 % 100.03 % -0.00 %  P 0.35 -0.03 %
Basque_Es, Catalan,
Andalucia, Extremadura
/Basque_Fr.
100.11 % -0.14% P 0.67 0.02% 100.02 % -0.01% P 0.41 -0.01%
Basque_Fr, Catalan,
Andalucia,
Extremadura /Basque_Es.
100.05 % -0.17% P 0.78 0.12% 100.05 % -0.04% P 0.43 0.06%
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for two of the ancestral populations always overlap, indicating that K=2 fits best the
structure present in our dataset.
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Finally, we analyzed linkage disequilibrium decay. In Figures 7 to 10, the proportion of
SNP pairs in each physical distance bin with r2>0.8 (Figs. 7, 9) or |D’|>0.8 (Figs. 8, 10)
are plotted. We considered separately all SNPs (Figs. 7, 8) and SNPs with minor allele
frequencies above 0.05 (Figs. 9, 10). The four graphs show the same pattern, in which
no single population consistently exhibits a slower LD decay.
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DISCUSSION
We have sought to verify whether the culturally isolated Basque population is also
genetically isolated to the point that would be especially appropriate  for genetic
association studies. To that effect, we have genotyped 123 SNPs in a ~1-Mb region in
chromosome 22 without any known genes, in two Basque populations as well as in
three other Iberian samples and in three population from North Africa. All populations
showed similar levels of genetic heterogeneity as measured by average heterozigosity.
The main source of differentiation within this sample set was Iberia vs. North Africa,
while Iberia was genetically homogeneous, and LD decayed with physical distance at
similar rates in all populations. Thus, we must conclude that, at least as gathered from
this genomic region, Basques do not exhibit the genomic properties that would make
them a particularly attractive population for association studies.
Our finding that Basques are not genetically differentiated contrasts sharply with
previous reports that showed them to be outliers in the genetic variation of western
Europe. However, the loci that with the largest allele frequency differences in previous
studies (Calafell and Bertranpetit, 1994) were ABO, RH, and other blood groups, that
is, glycoproteins of the red-cell membrane. It is tempting to speculate, then, that such
differences were not due to founder effects and subsequent reduced gene flow, but
rather that they were the result of microgeographical natural selection, possibly linked
to pathogens.
The low genetic differentiation and lack of internal substructure within Iberian
population actually facilitates the design of case-control studies, since patients and
healthy controls from different regions in Spain can be freely pooled without population
substructure producing spurious associations.
We have analyzed 66,240 genotypes from 1 Mb of the human genome in five samples
from Iberia and three from North Africa, making it probably the largest genetic survey
of this area. However, it is also limited to this particular genome segment, and results
should be treated with caution. A broader study, with a wider geographical and genomic
coverage would be needed to decide whether gene content has biased our results or to
uncover other sources of genetic differentiation within Spain.
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FINAL REMARKS
METABOLIC NETWORK AND DISEASE SUSCEPTIBILITY
Hepcidin, the long awaited iron hormone, is the principal downregulator of the transport
of iron across the small intestine and the placenta, and its release from macrophages.
The present view is that hepcidin downregulates iron efflux from the intestine and
macrophages by binding FPN and, following complex internalisation, leads to FPN
degradation. In HFE, TfR2, and HJV related HC, hepatic expression or serum/urine
levels of HAMP are inappropriately low.42 43 53 54 Its expression in the liver is also
significantly impaired in HFE, TfR2, and HJV knockout mice24 55–57 and hepatic
deposition of iron in HFEKO animals can be prevented by hepcidin overexpression.58
These findings suggests a unifying pathogenic model for all forms of HC in which HFE,
TfR2, and HJV are all independent but complimentary regulators of hepcidin synthesis
in the liver (fig 1). Hypothetically, these three proteins may be important for sensing
circulatory iron and turning on hepcidin gene transcription, albeit with different
mechanisms and functional impact. As the central role in iron homeostasis and in
hemochromatosis disease development of this small peptide was established, we
decided to analyze the variability in the promoter and in the coding region in 84 Italian
subjects that presented symptoms of iron overload and resulted negative for the three
reported HFE  mutations. In the screening study a total of 420 amplicons were analyzed
and 5 different variants were detected. Of these 5 variants 3 were in non-coding region
and two in were found in exons, but resulted synonymous mutations.  These results
reflect a picture of high degree of conservations, especially if we consider that the
subject that entered in the study share some defects in iron metabolism pathways and
are not representative of general population. In three different studies several rare
variants in HAMP gene region are reported  as causative for hemochromatosis disease.
In our case we can not rule out a possible involvement of the variant detected in iron
overload phenotype, but it is difficult to demonstrate.  From our results we can conclude
that even though hepcidin plays a pivotal role in iron homeostasis regulations the
molecular variability of the HAMP gene give only a marginal contribution in iron
overload phenotypes.
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NEW APPROACH ON CANDIDATE GENE STUDIES
The present data suggest that HP promoter polymorphism can be used as a marker in
human population genetic studies. We determined the frequency distribution of HP
alleles and promoter polymorphism using PCR and direct DNA sequencing of PCR
products. We sequenced a 300-bp genomic DNA fragment of the HP promoter region
and found population specificity of the distribution of not only the HP alleles but also
the base substitutions at the promoter region and the haplotypes.
The  61C and  101G substitutions appear to be specific to individuals of African origin,
because they were not detected in Europeans or Asians. Interestingly, the  61C
substitution, located in one of three interleukin 6 responsive elements (Oliviero and
Cortese 1989), was also found in African Americans, with the HP 2,1mod phenotype
having a lower serum Hp level (Maeda 1991).
We have also seen this substitution in South African Xhosas at frequencies that are
similar to those observed in Ghanaians (results not shown). We previously reported that
the  61AVC and  101CVG substitutions were strongly associated with
ahaptoglobinemia and hypohaptoglobinemia, respectively, which are frequent in
African populations (Teye et al. 2003). The uniqueness of the  61C and 101G
substitutions in the African population is highlighted by the fact that they are associated
with the HP*2 and HP*1S alleles, respectively. The  104A substitution also appeared to
be specific to African populations because we detected only one (1%) allele out of 100
European alleles, whereas the Ghanaian population had as many as 92 (37.4%) out of
246 alleles and the Chinese population had none. The South African white population is
estimated to be 93% European and 7% non-European (a mix of people of southern
African and Asian descent) (Botha et al. 1975). Therefore the probability of the one
104A substitution coming from an African gene cannot be excluded. The European
population showed a higher frequency of the  242T substitution, which was the only
major marker for this population. The  55G and  191G substitutions occurred at high
and low frequencies, respectively, in all study populations, so they may not be suitable
for population genetic studies. However, the  61C,  101G,  104A, and  242T
substitutions could be useful for population genetic studies in African and European
populations.
The Chinese population appears to be less polymorphic with respect to the SNPs than
the African or European populations. However, the presence of the HP*del allele and
the absence of the HP*1F allele serve as unique markers within the Chinese population.
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The data revealed a dense SNP map within the HP promoter region, containing as many
as six polymorphic sites within a short fragment of 300 bp. Thus, together with other
markers, HP polymorphism at the allele and promoter levels may provide new pieces to
the anthropogenetic puzzle of human migration and population differentiation. All the
substitutions can be detected in a single PCR and sequencing reaction because the DNA
fragment is less than 400 bp, making it simple and convenient to analyze.
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POPUALTIONS IN ASSOCIATION STUDIES
Isolate populations have demonstrate to be effective for  mutation discovery involved in
rare Mendelian disorders, now is largely accepted that isolated populations of varied
types will proof to be as effective in elucidating the genetic basis of complex disease.
Although accepted the model behind the genetic of complex diseases it is completely
different to the one behind the genetic of rare diseases, so it is not possible to transfer
the good results obtained by the use of isolated populations in rare disease study, in
faithful expectation from their utilization in complex disease research. Two main
qualities are addressed to isolated populations to support their candidacy: increased
levels of LD and lower indices of heterozigosity. These promising qualities were
extensively investigated in only one study on a Micronesian isolated population. Except
this single study there aren’t other available consistent data, especially from European
country, where several putative isolated populations are recently proposed as ideal
source of subject for successful case control study. Aim of our study is to verify if  on
the basis of cultural evaluations and from fragmentary molecular data is possible to
elect a hypothetical isolated population better than other general populations in gene
finding in association study. To do that we genotyped a final number of 123 SNPs
selected in a geneless region of 1 Mb in the chromosome 22 in eight populations: two
Basque populations that are considered as isolated populations, three general Iberian
population: from Catalonia region, Extremadura region and Andalusia region and
finally three north African populations. From the analysis of genotype data a picture of
extended homogeneity is emerged. The two Basque populations present neither the
larger LD signals nor the lowest levels of heterozigosity.  From the analysis of
populations diversity a pattern of genetic homogeneity arose between the 5 Iberian
populations, with no significative values of Fst. Only considering the three African
populations the genetic divergence became appreciable and statistically significative.
Although significative the level of differentiation between Iberian and North African
populations is less deep then those reported in previous study based on the analysis of
the y chromosome and mitochondrial DNA. In particular when we perform the structure
analysis considering all 123 SNPs we can observe that the high degree of genetic
homogeneity of Iberian populations is shared also with north African populations.
When we use the 14 SNPs with the higher Fst values we became able to distinguish
populations at continental levels, but we must remember that the real picture is the one
where the contribution of all the different loci is considered. Backward  to Basque issue
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our results clearly indicate that Basque do not present the expected enhanced quality
required for better results in gene finding association studies. Also clear is that the lack
of those enhanced qualities is due to the fact that the two Basque populations for the
variants we tested results absolutely not isolated. Although we must be careful in stating
general considerations from the analysis of a single genomic region of only 1 Mb, our
results supply several interesting new indications and suggest interesting questions.
Basque are considered isolated on the basis of cultural issues and from results from
several genetic studies based on analysis of molecular variability of y chromosome and
mt-DNA and from analysis of variants in HLA region. Results from y chromosome and
from mt-DNA have proved to be useful tools in defining populations genetic identity
and in reconstructing population history, but is difficult to assess to which  extent those
molecular marker are representative of the whole genomic variability. Moreover results
from the analysis of HLA region were largely used to describe molecular diversity in
populations and from the analysis of such variants derived  the results that with more
strength indicates Basques as a genetic isolate. About this results it is possible to risk a
consideration, as HLA region is the genomic region mainly involved in the immunity
response to pathogens it is possible that the strong signal of isolation in Basques is
increased by the effect of natural selection.
Although our data have not a genome wide scale, they are related to a genomic region
where the impact of natural selection is supposed to be minimal and the net of marker
considered is dense enough for a good evaluation of linkage disequilibrium decay. From
our data appear clear that from cultural issues and from molecular studies that stress
population diversity it is not possible elaborate reliable consideration on populations
genomic structure, concluding that genetic isolation has to be deeply empirically
investigated and tested to be proposed  as powerful  tool in association studies.
Moreover the picture of low levels heterozigosity and the high degree of homogeneity
emerged in our results could suggest that a possible alternative to isolated populations in
association study is to use populations selected with light demographic rules in order to
widen the subject recruitment basin and gain the possibility to collect wider and
phenotypically more homogenous cohorts of patients.
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